

令和 6(2024)年度 研究成果の刊行に関する一覧表 【書籍】

著者氏名		論文タイトル名	書籍全体の 編集者名	書籍名	出版社名	出版地	出版年	ページ	関連
1)	保坂哲也	B 型慢性肝炎の治療（核酸アナログ）	三田英治 平松直樹	必ず役立つ！肝炎診療バイブル（改訂 6 版）	メディカ出版	大阪	2024	129-138	○
2)	保坂哲也	・ 肝炎ウイルスマーカー ・ B 型肝炎に対する治療薬 ・ B 型慢性肝炎（病態）	日本肝臓学会	肝臓専門医テキスト（改訂第 4 版）	南江堂	東京	2024	91-93 186-191 308-312	○
3)	清水雅仁		一般財団法人 日本肝臓学会	肝臓専門医テキスト 改訂第 4 版	南江堂	東京	2024		○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
1)	Nishimura T, Tada T, <u>Akita T</u> , Kondo R, Suzuki Y, Imajo K, Kokubu S, Abe T, Kuroda H, Hirooka M, Hiasa Y, Nogami A, Nakajima A, Ogawa S, <u>Toyoda H</u> , Oeda S, Takahashi H, Eguchi Y, Sugimoto K, Yano H, <u>Tanaka J</u> , Moriyasu F, Kage M, Kumada T, Iijima H	Diagnostic performance of attenuation imaging versus controlled attenuation parameter for hepatic steatosis with MRI-based proton density fat fraction as the reference standard: a prospective multicenter study	Journal of Gastroenterology			in press	○
2)	Kaneyasu Y, Fujiwara H, <u>Akita T</u> , <u>Tanaka J</u> , Shibata Y, Nakagawa T, Koh I, Hirata E, Hyodo M, Miyamoto T, Murakami Y, Nishibuchi I, Imano N, Nagata Y, Kudo Y	Suppressive effect of vitamin K2 (menatetrenone) against bone mineral density loss after radiotherapy in uterine cancer patients	Japanese Journal of Radiology			in press	
3)	Tada T, Kumada T, <u>Toyoda H</u> , Yasuda S, Koshiyama Y, <u>Akita T</u> , Kodama Y, <u>Tanaka J</u>	Association of liver fibrosis progression with non-liver-related mortality in metabolic dysfunction-associated steatotic liver disease	Hepatology Research			in press	
4)	Nagata T, Chimed-Ochir O, Yumiya Y, <u>Tanaka J</u> , Kuwabara M, Kitahara K, Ohge H, Kubo T	Effect of individual preventive practices on COVID-19 infection: an analysis of big data collected at PCR testing centers in Hiroshima, Japan	Virus Research	25(1)	681	2025	
5)	Ota Y, Yumiya Y, Chimed-Ochir O, Hasegawa A, Yoshida T, Nagata T, <u>Tanaka J</u> , Ohge H, Kuwabara M, Kubo T	Characteristics of patients with COVID-19 and smell and/or taste disorders depending on different virus strains: a cross-sectional study in Hiroshima, Japan	BMJ Open	15(2)	e088377	2025	
6)	Ohira M, Imaoka Y, Sato K, Imaoka K, Bekki T, Yano T, Nakano R, Sakai H, Kuroda S, Tahara H, Ide K, Kobayashi T, Tanaka Y, <u>Tanaka J</u> , Ohdan H	A phase I/II study of adoptive immunotherapy using donor liver graft-derived NK cell-enriched immune cells to prevent severe infection after liver transplantation	PLoS ONE	20(1)		2025	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
7)	Nomura N, Matsumoto H, Asano K, Hayashi Y, Yokoyama A, Nishimura Y, Hashimoto N, Sakagami T, Fukunaga K, Hizawa N, Yamasaki A, Nagase H, Hattori N, Kondo M, Harada N, Sugiura H, Miki M, Kimura T, Toyoshima M, Matsuno O, Koh H, Kita T, Tomioka H, Tomii K, Ohnishi H, Takata S, Tobino K, Imokawa S, Sunadome H, Nagasaki T, Oguma T, Tanabe N, Hirai T, Ikeda M, Okamura K, Terada-Hirashima J, Hojo M, Isogai S, Imaizumi K, Horiguchi T, Hirano R, Fujita M, Fujisawa T, Suda T, Takaki Y, Higaki N, Miyamoto S, Nakashima T, Iwamoto H, Mikami K, Minami T, Takahashi R, Kijima T, Hoshino M, Tsuji T, Hiraoka N, Ikeue T, Sugita T, Kunichika N, Tomari S, Okochi Y, Mato N, Hagiwara K, Dobashi K, Taooka Y, Machida K, Inoue H, Tanosaki T, Masaki K, Sano A, Iwanaga T, Higashimoto Y, Tohda Y, Matsumoto M, Takatsuki K, Nagata K, Tachikawa R, Kaneko M, Nagano T, Yamane M, Yoshida C, Seto Y, Kaneko Y, Takayama K, Terada S, Nishi K, Tajiri T, Niimi A, Nakamura S, Wakahara K, Ito T, Nakano T.F, Yamashita T, Seri Y, Mizumori Y, Tsukamoto H, Kagami R, Nakahara Y, Kawamura T, Ishii Y, Hidaka K, Kadowaki T, Minakuchi M, Tsuboi T, Tamaki S, Matsuki T, Kida H, Tomita K, Abe T, Shindoh J, Taniguchi A, Miyahara N, Azuma M, Kataoka M, Ogawa H, Matsumoto T, Aihara K, Nakagome K, Nagata M, Miyajima S, Hashimoto K, Shiota T, Yamaguchi M, Nakano Y, Otsuka K, Yasuo M, Hanaoka M, Yamada T, Shirai T, Iwasaki Y, Mineshita M, Tsuburai T, Komase Y, Hasegawa K, Kita H, Murakami K, Ichinose M, Kutsuzawa T, <u>Tanaka J</u> , Kono Y, Abe S, Nakamura M, Orimo M, Tagaya E, Matsuda T, Harada T, Taniguchi H, Iijima H, Kawabata H, Yatera K, Masuko H, Morishima Y, Nakanishi M, Yamamoto N, Inoue S, Hamada K, Yamaji Y, Hirano T, Matsunaga K, Sato Y	Refractory phenotype of Aspergillus-sensitized asthma with bronchiectasis and allergic bronchopulmonary aspergillosis	Journal of Allergy and Clinical Immunology: Global	4(1)		2025	
8)	Gotoh T, Kumada T, Ogawa S, Niwa F, <u>Toyoda H</u> , Hirooka M, Koizumi Y, Hiasa Y, <u>Akita T</u> , <u>Tanaka J</u> , <u>Shimizu M</u>	Comparison Between Attenuation Measurement and the Controlled Attenuation Parameter for the Assessment of Hepatic Steatosis Based on MRI Images	Liver International	45(1)		2025	○
9)	Mirzaev U.K, Yoshinaga Y, Baynazarov M, Ouoba S, Ko K, Phyo Z, Chhoung C, Akuffo G.A, <u>Sugiyama A</u> , <u>Akita T</u> , Takahashi K, Fukuma S, <u>Tanaka J</u>	Diagnostic accuracy of hepatitis E virus antibody tests: A comprehensive meta-analysis	Hepatology Research			in press	○
10)	Phyo Z, Tanaka S, <u>Sugiyama A</u> , Ko K, Takahashi K, Mirzaev U.K, Akuffo G.A, Chhoung C, <u>Akita T</u> , Kozuki M, Sakamori R, <u>Tanaka J</u>	Unveiling the dynamics of hepatitis C virus transmission among injection drug users and men who have sex with men: A comprehensive study in Japan	Hepatology Research			in press	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
11)	Yumiya Y, Kawanishi K, Chimed-Ochir O, Kishita E, Sugiyama A , Tanaka I , Kubo T	Effectiveness of COVID-19 mRNA vaccine in preventing infection against Omicron strain: Findings from the Hiroshima Prefecture COVID-19 version J-SPEED for PCR center	PLOS Global Public Health	4(4)	e0003071	2024	
12)	Akita T , Kurisu A, Masumoto F, Bunthen E, Sugiyama A , Kawaoka T, Imamura M, Aikata H, Seike M, Akuta N, Kumada T, Karino Y, Chayama K, Tanaka I	Health-related quality of life after sustained virological response to treatment for hepatitis C	Hiroshima Journal of Medical Sciences	73(1-2)	1-7	2024	○
13)	Sada H, Hinoi T, Niitsu H, Ohdan H, Yamamoto S, Endo S, Hida K, Kinugasa Y, Enomoto T, Maruyama S, Konishi F, Watanabe M, Sugihara K, Murata K, Horie H, Okajima M, Yamagishi S, Fujii S, Hazama S, Miyake Y, Kurose Y, Takii Y, Hayashi K, Munakata Y, Naito T, Saida Y, Shimamura T, Suda T, Miyajima N, Tanaka I , Goto M, Sakamoto K, Kinugasa Y, Saito S, Kubo Y, Okita K, Furuhashi T, Yatsuoka T, Tashiro J, Yamaguchi S, Ito M, Saito N, Hamada M, Kokuba Y, Kinjo Y, Sakai Y, Ueki T, Naito M, Kuroyanagi H, Ueno M, Akamoto S, Nishimura J, Hasegawa J, Kanazawa A, Maeda K, Hirakawa K, Yasui M, Tanaka K, Okuda J, Akagi T, Inomata M, Kitano S, Yamamoto D, Bando H, Shiozawa K, Kanehira E	Right-sided versus left-sided colorectal cancer in elderly patients: a sub-analysis of a large multicenter case-control study in Japan	Surgery Today	54(10)	1173-1183	2024	
14)	Chhoung C, Ko K, Ouoba S, Phyo Z, Akuffo G.A, Sugiyama A , Akita T , Sasaki H, Yamamoto T, Takahashi K, Tanaka I	Sustained applicability of SARS-CoV-2 variants identification by Sanger Sequencing Strategy on emerging various SARS-CoV-2 Omicron variants in Hiroshima, Japan	BMC Genomics	25(1)	1063	2024	
15)	Ko K, Lokteva L.M, Akuffo G.A, Phyo Z, Chhoung C, Bunthen E, Ouoba S, Sugiyama A , Akita T , Rattana K, Vichit O, Takahashi K, Tanaka I	A comparative study of extraction free detection of HBV DNA using sodium dodecyl sulfate, N-lauroylsarcosine sodium salt, and sodium dodecyl benzene sulfonate	Scientific Reports	14(1)	25442	2024	○
16)	El Ekiaby M, Tanaka I , van Drimmelen H, Allain JP, Lelie N	Infectivity of Hepatitis B Virus Surface Antigen-Positive Plasma With Undetectable HBV-DNA: Can HBsAg Screening Be Discontinued in Egyptian Blood Donors?	Journal of Viral Hepatitis	31(11)	700-709	2024	○
17)	Satake M , Sugiyama M, Mizokami M, Tanaka I	Incidences of new hepatitis B infection and anti-hepatitis B core-negative occult hepatitis B infection among Japanese blood donors in relation to anti-hepatitis B surface antigen levels	Journal of Medical Virology	96(7)	e29823	2024	○
18)	Ouoba S, Sugiyama A , Ko K, Mirzaev U.K, Abe K, Bunthen E, Phyo Z, Khalilov K.K, Kurisu A, Akita T , Takahashi K, Sasaki H, Yamamoto T, Tanaka I	Development of a unit conversion tool for five quantitative anti-spike assays and agreement analysis of three qualitative anti-nucleocapsid assays for SARS-CoV-2	Journal of Medical Virology	96(8)	e29826	2024	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
19)	Shimohara C, Kagaya A, <u>Akita T</u> , Tsukue R, Shimohara A, Machizawa M.G, Yamawaki S, <u>Tanaka J</u> , Okamura H	Changes in interoception before and after treatment in patients with alcohol use disorder	Neuropsychopharmacology Reports	44(4)	792-797	2024	
20)	Phyo Z, Ko K, Ouoba S, <u>Sugiyama A</u> , Mirzaev U.K, Akuffo G.A, Chhoung C, <u>Akita T</u> , <u>Tanaka J</u>	Intermediate hepatitis C virus (HCV) endemicity and its genotype distribution in Myanmar: A systematic review and meta-analysis	Plos One	19(9)	e0307872	2024	○
21)	Akuffo G.A, Ouoba S, Ko K, Chhoung C, Phyo Z, Mirzaev U.K, <u>Sugiyama A</u> , <u>Akita T</u> , <u>Tanaka J</u>	Assessing the diagnostic accuracy of serological tests for hepatitis delta virus diagnosis: a systematic review and meta-analysis	Scientific Reports	14(1)	18475	2024	○
22)	Kurose M, Yamamoto A, Elsayed A.M.A, Lawal-Ayinde B.M, Nomura T, Higashiura A, Irie T, Fukushima M, Kanda M, Tahara H, Morita D, Kuroda T, Ko K, Takahashi K, <u>Tanaka J</u> , Sakaguchi T	Viral coexistence and insertional mutations in the ORF8 region of SARS-CoV-2: A possible mechanism of nucleotide insertion	Virus Research	350()	199478	2024	
23)	Razavi-Shearer DM, Buti M, Tacke F, Terrault NA, Zeuzem S, Abbas Z, Aghemo A, Akarca US, Al Masri NM, Alalwan AM, Blomé MA, Aleman S, Alghamdi AS, Alghamdi M, Alghamdi S, Al-Hamoudi WK, Ali E, Aljumah AA, Altraif IH, Amarsanaa J, Asselah T, Baatarkhuu O, Babameto A, Ben-Ari Z, Berg T, Biondi MJ, Braga WSM, Brandao-Mello CE, Brown RS, Brunetto MR, Cabezas J, Cardoso M, Chan HLY, Cheinquer H, Chen CJ, Chen PJ, Chien CH, Child H, Chuang WL, Garza LEC, Coco B, Coffin CS, Coppola N, Cornberg M, Craxi A, Crespo J, Cuko L, De Ledinghen V, Duberg AS, Etzion O, Ferraz MLG, Ferreira PRA, Forns X, Foster GR, Fung J, Gaeta GB, García-Samaniego J, Genov J, Gheorghe LS, Gholam PM, Gish RG, Glenn J, Goldis A, Hamid SS, Hercun J, Hsu YC, Hu CC, Huang JF, Idilman R, Jafri WSM, Janjua N, Jelev D, Jerkeman A, Jia JD, Kåberg M, Kaita KDE, Kao JH, Khan AG, Kim DY, Kondili LA, Lagging M, Lampertico P, Lázaro P, Lazarus J, Lee MH, Lim YS, Lobato CMO, Macedo G, Marinho RT, Marotta PJ, Martins A, Mendes-Correa MC, Méndez-Sánchez N, Navas MC, Ning Q, Örmeci N, Orrego M, Osiowy C, Pan CQ, Pessoa MG, Piracha ZZ, Pop C, Ramos JAP, Qureshi H, Raimondo G, Ramji A, Razavi-Shearer K, Ribeiro S, Ríos-Hincapié CY, Rodríguez M, Rosenberg WMC, Roulot D, Ryder SD, Saeed U, Safadi R, Sanai FM, Sanchez-Avila JF, Santantonio TA, Sarrazin C, Seto WK, Shouval D, Simonova MY, <u>Tanaka J</u> , Tergast TL, Tsendsuren O, Valente C, Villalobos-Salcedo JM, Voeller AS, Waheed Y, Wong GLH, Wong VWS, Wu JC, Yang H, Yip TCF, Yu ML, Yuen MF, Yurdaydin C, Zuckerman E, Razavi HA	Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories	Journal of Hepatology	80(2)	232-242	2024	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
24)	Bastard P, Gervais A, Taniguchi M, Saare L, Särekanu K, Le Voyer T, Philippot Q, Rosain J, Bizien L, Asano T, Garcia-Prat M, Parra-Martínez A, Migaud M, Tsumura M, Conti F, Belot A, Riviére JG, Morio T, Tanaka J , Javouhey E, Haerynck F, Duvlis S, Ozcelik T, Keles S, Tandjaoui-Lambiotte Y, Escoda S, Husain M, Pan-Hammarström Q, Hammarström L, Ahliah G, Haidar AA, Soudee C, Arseguet V, Abolhassani H, Sahanic S, Tancevski I, Nukui Y, Hayakawa S, Chrousos GP, Michos A, Tatsi EB, Filippatos F, Rodriguez-Palmero A, Troya J, Tipu I, Meyts I, Roussel L, Ostrowski SR, Schidlowski L, Prando C, Condino-Neto A, Cheikh N, Bousfiha AA, El Bakkouri J, Peterson P, Pujol A, Lévy R, Quartier P, Vinh DC, Boisson B, Béziat V, Zhang SY, Borghesi A, Pession A, Andreacos E, Marr N, Mentis AFA, Mogensen TH, Rodríguez-Gallego C, Soler-Palacin P, Colobran R, Tillmann V, Neven B, Trouillet-Assant S, Brodin P, Abel L, Jouanguy E, Zhang Q, Martínón-Torres F, Salas A, Gómez-Carballa A, Gonzalez-Granado LI, Kisand K, Okada S, Puel A, Cobat A, Casanova JL	Higher COVID-19 pneumonia risk associated with anti-IFN- α than with anti-IFN- ω auto-Abs in children	Journal of Experimental Medicine	221(2)	e20231353	2024	
25)	Toyoda H , Tada T, Uojima H, Nozaki A, Chuma M, Takaguchi K, Hiraoka A, Abe H, Itobayashi E, Matsuura K, Atsukawa M , Watanabe T, Shimada N, Nakamuta M, Kojima M, Tsuji K, Mikami S, Ishikawa T, Yasuda S, Tsutsui A, Arai T, Kumada T, Tanaka Y, Tanaka J , Chayama K	Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma	Journal of Gastroenterology and Hepatology	39(5)	949-954	2024	○
26)	Ishimaru T, Yamaguchi T, Saito T, Hattori Y, Ono T, Arai Y, Hasegawa Y, Shiga H, Tamaki K, Tanaka J , Tsuga K, Abekura H, Miyawaki S, Maeda-Lino A, Mikami S, Gotouda A, Satoh K, Shimizu K, Kato Y, Namita T	Actual state of the diurnal masseteric electromyogram: Differences between awareness and non-awareness of awake bruxism	Journal of Prosthodontic Research	68(3)	456-465	2024	
27)	Kumada T, Toyoda H , Ogawa S, Gotoh T, Yoshida Y, Yamahira M, Hirooka M, Koizumi Y, Hiasa Y, Tamai T, Kuromatsu R, Matsuzaki T, Suehiro T, Kamada Y, Sumida Y, Tanaka J , Shimizu M	Diagnostic performance of shear wave measurement in the detection of hepatic fibrosis: A multicenter prospective study	Hepatology Research	54(9)	851-858	2024	○
28)	Kumada T, Toyoda H , Ogawa S, Gotoh T, Suzuki Y, Sugimoto K, Yoshida Y, Kuroda H, Kamada Y, Sumida Y, Ito T, Akita T , Tanaka J	Severe hepatic steatosis promotes increased liver stiffness in the early stages of metabolic dysfunction-associated steatotic liver disease	Liver International	44(7)	1700-1714	2024	○
29)	Kumada T, Toyoda H , Ogawa S, Gotoh T, Suzuki Y, Imajo K, Sugimoto K, Kakegawa T, Kuroda H, Yasui Y, Tamaki N, Kurosaki M, Izumi N, Akita T , Tanaka J , Nakajima A	Advanced-fibrosis leads to overestimation of steatosis with quantitative ultrasound in individuals without hepatic steatosis	Ultrasonography	43(2)	121-131	2024	○
30)	Sakoi N, Mori Y, Tsugawa Y, Tanaka J , Fukuma S	Early-Stage Chronic Kidney Disease and Related Health Care Spending	JAMA Network Open	7(1)	e2351518	2024	
31)	Kariyama K, Kawanaka M, Nouse K, Wakuta A, Shiota S, Kurisu A, Sugiyama A , Akita T , Kumada T, Tanaka J	Identification of risk groups for advanced liver fibrosis in the general population using the Fibrosis-3 index	JGH Open	8(7)	e70010	2024	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
32)	Ogawa S, Kumada T, Gotoh T, Niwa F, <u>Toyoda H, Tanaka J, Shimizu M</u>	A comparative study of hepatic steatosis using two different qualitative ultrasound techniques measured based on magnetic resonance imaging-derived proton density fat fraction	Hepatology Research	54(7)	638-654	2024	○
33)	<u>Sugiyama A</u> , Takafuta T, Sato T, Kitahara Y, Yoshinaga Y, Abe K, Chanroth C, Ataa AG, Phyo Z, Kurisu A, Ko K, <u>Akita T</u> , Kishita E, Kuwabara M, <u>Tanaka J</u>	Natural course of post-COVID symptoms in adults and children	Scientific reports	14(1)	3884	2024	
34)	Mirzaev U.K, Ouoba S, Ko K, Phyo Z, Chhoung C, Ataa A.G, <u>Sugiyama A, Akita T, Tanaka J</u>	Systematic review and meta-analysis of hepatitis E seroprevalence in Southeast Asia: a comprehensive assessment of epidemiological patterns	BMC Infectious Diseases	24(1)	525	2024	○
35)	Sok S, Chhoung C, Sun B, Ko K, <u>Sugiyama A, Akita T, Fukuma S, Tanaka J</u>	Knowledge of hepatitis B infection, hepatitis B vaccine, and vaccination status with its associated factors among healthcare workers in Kampot and Kep Provinces, Cambodia	BMC Infectious Diseases	24(1)	658	2024	○
36)	Abe K, <u>Sugiyama A</u> , Ito N, Miwata K, Kitahara Y, Okimoto M, Mirzaev U, Kurisu A, <u>Akita T</u> , Ko K, Takahashi K, Kubo T, Takafuta T, <u>Tanaka J</u>	Variant-specific symptoms after COVID-19: a hospital-based study in Hiroshima	Journal of epidemiology	34(5)	238-246	2024	
37)	Mirzaev U.K, Ko K, Bunthen E, Phyo Z, Chhoung C, Ataa A.G, <u>Sugiyama A, Akita T, Takahashi K, Tanaka J</u>	Epidemiological assessment of hepatitis E virus infection among 1565 pregnant women in Siem Reap, Cambodia using an in-house double antigen sandwich ELISA	Hepatology Research	54(10)	899-911	2024	○
38)	Okada K, Nakayama Y, Xu J, Cheng Y, <u>Tanaka J</u>	A nation-wide medical record database study: Value of hepatitis B surface antigen loss in chronic hepatitis B patients in Japan	Hepatology Research	54(11)	1004-1015	2024	○
39)	Kimura M, Nishikawa T, <u>Shimakami T</u> , Terashima T, Horii R, Fukuda M, Yoshita M, Takata N, Hayashi T, Funaki M, Nio K, Takatori H, Arai K, Yamashita T, Honda M, <u>Tanaka J</u> , Kaneko S, Yamashita T	Higher FIB-4 index at baseline predicts development of liver cancer in a community-based cohort with viral hepatitis	Global Health & Medicine	6(6)	404-415	2024	○
40)	Yamaguchi D, Chimed-Ochir O, Yumiya Y, Kishita E, <u>Akita T, Tanaka J</u> , Kubo, T	Potential Risk Factors to COVID-19 Severity: Comparison of SARS-CoV-2 Delta- and Omicron-Dominant Periods	International Journal of Environmental Research and Public Health	21(3)	322	2024	
41)	<u>Toyoda H</u> , Koshiyama Y, Yasuda S, Kumada T, Chayama K, <u>Akita T, Tanaka J</u>	Effect of previous infection with hepatitis B virus on the incidence of hepatocellular carcinoma after sustained virologic response in patients with chronic hepatitis C virus infection	Journal of Viral Hepatitis	31(3)	137-142	2024	○
42)	Kurisu A, <u>Sugiyama A, Akita T</u> , Takumi I, Yamamoto H, Iida K, <u>Tanaka J</u>	Incidence and prevalence of epilepsy in Japan: a retrospective analysis of insurance claims data of 9,864,278 insured persons	Journal of epidemiology	34(2)	70-75	2024	
43)	Yamagishi N, Ando N, Yoshimasa T, Toda S, Sobata R, Goto N, Matsubayashi K, <u>Satake M, Tani Y.</u>	The first case of transfusion-transmitted hepatitis B virus genotype I in Japan.	Transfusion	Online ahead of print		2025	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
44)	Tai-Chung Tseng, <u>Tetsuya Hosaka</u> , Mei-Hung Pan, Chun-Jen Liu, Fumitaka Suzuki, Chien-Jen Chen, Tung-Hung Su, Hiromitsu Kumada, Wan-Ting Yang, Hung-Chih Yang, Chen-Hua Liu, Pei-Jer Chen, Hwai-I Yang, Jia-Horng Kao	Higher Level of Hepatitis B Surface Antigen Associated with Delayed Development of Hepatocellular Carcinoma in Immune-tolerant Patients.	Hepatology	in press		2025	○
45)	Tanaka T, <u>Koga H</u> , Suzuki H, Iwamoto H, Sakaue T, Masuda A, Nakamura T, Akiba J, Yano H, Torimura T, Kawaguchi T.	Anti-PD-L1 antibodies promote cellular proliferation by activating the PD-L1-AXL signal relay in liver cancer cells.	Hepatol Int	18(3)	984-997	2024	
46)	Suzuki H, Iwamoto H, Tanaka T, Sakaue T, Imamura Y, Masuda A, Nakamura T, <u>Koga H</u> , Hoshida Y, Kawaguchi T.	Fibroblast growth factor inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma.	Hepatol Int	18(2)	610-622	2024	
47)	Masuda A, Nakamura T, Iwamoto H, Suzuki H, Sakaue T, Tanaka T, Imamura Y, Mori N, <u>Koga H</u> , Kawaguchi T.	Ex-vivo expanded CD34+ cell transplantation alleviates fibrotic liver injury via innate immune modulation in metabolic dysfunction-associated steatohepatitis mice.	Cytherapy	26(8)	899-909	2024	
48)	Nakamura T, Masuda A, Kako M, Enomoto H, Kaibori M, Fujita Y, Tanizawa K, Ito T, Fujimori Y, Fukami K, Hazama T, Iwamoto H, Kako Y, Kobayashi K, <u>Koga H</u> , Nagafuji K, Ohtake T, Suzuki H, Takashima T, Tsukiyama T, Uojima H, Yamahara K, Yamakado K, Yamamoto H, Yoh K, Yoshihara S, Kawamoto A, Nishiguchi S, Kobayashi S, Torimura T, Kawaguchi T.	Hepatic arterial infusion of autologous CD34+ cells for hepatitis C virus-related decompensated cirrhosis: A multicenter, open-label, exploratory randomized controlled trial.	Regen Ther	27	455-463	2024	
49)	Suzuki H, Sakai M, Iwamoto H, Shimose S, Niizeki T, Nakano M, Shirono T, Noda Y, Moriyama E, Kuromatsu R, <u>Koga H</u> , Kawaguchi T.	The Immune Inductive Role of Hepatic Arterial Infusion Chemotherapy Prior to Atezolizumab Plus Bevacizumab Combination Therapy in Hepatocellular Carcinoma.	Gastro Hep Adv	3(4)	506-509	2024	
50)	Masubuchi H, Imamura Y, Kawaguchi T, <u>Koga H</u> .	Leucine drives LAT1-related SNAIL upregulation in glucose-starved pancreatic cancer cells.	Med Mol Morphol	58(1)	23-33	2024	
51)	Sakai M, Iwamoto H, Shimose S, Niizeki T, Nakano M, Shirono T, Noda Y, Moriyama E, Suzuki H, <u>Koga H</u> , Kuromatsu R, Kawaguchi T.	Dose-Reduction of Bevacizumab in Atezolizumab plus Bevacizumab Therapy Extends Treatment duration with Disease Control in Patients with Hepatocellular Carcinoma.	Oncology	12	1-12	2024	
52)	Sakaue T, <u>Koga H</u> , Iwamoto H, Nakamura T, Masuda A, Tanaka T, Suzuki H, Suga H, Hirai S, Hisaka T, Naito Y, Ohta K, Nakamura KI, Selvendiran K, Okabe Y, Torimura T, Kawaguchi T.	Pancreatic Juice-Derived microRNA-4516 and microRNA-4674 as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma.	Gastro Hep Adv	3(6)	761-772	2024	
53)	Sakaue T, Dorayappan KDP, Zingarelli R, Khadraoui W, Anbalagan M, Wallbillich J, Bognar B, Wanner R, Cosgrove C, Suarez A, <u>Koga H</u> , Maxwell GL, O'Malley DM, Cohn DE, Selvendiran K.	Obesity-induced extracellular vesicles proteins drive the endometrial cancer pathogenesis: therapeutic potential of HO-3867 and Metformin.	Oncogene	43(49)	3586-3597	2024	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
54)	Moriyama E, Shimose S, Niizeki T, Iwamoto H, Tanaka M, Shirono T, Noda Y, Nakano M, Kuromatsu R, <u>Koga H</u> , Kawaguchi T.	Efficacy of Atezolizumab Plus Bevacizumab-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.	Curr Oncol	31(10)	5821-5831	2024	
55)	Suzuki H, Fukuda M, Shirono T, Kondo R, Tanaka T, Niizeki T, Akiba J, <u>Koga H</u> , Kawaguchi T.	A Rare Case of Primary Hepatic Undifferentiated Pleomorphic Sarcoma: Exploring Cancer-related Gene Mutations.	Intern Med	doi: 10.2169/internmedicine.4368-24.		2024	
56)	Inukai Y, Ito T, Yokoyama S, Yamamoto K, Imai N, Ishizu Y, Honda T, Shimizu T, Hattori M, Takeyama T, Ando Y, Nishikawa T, Morita K, <u>Toyoda H</u> , Ishigami M, Kawashima H	Impact of cardiometabolic factors on fibrosis progression in patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease.	J Dig Dis			in press	
57)	Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ohama H, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Tada F, Nakamura S, Nakamura Y, Nouse K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Tanaka K, Tanaka H, Koshiyama Y, Kanayama Y, Noritake H, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T	Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice.	Hepatol Res			in press	
58)	Kimura M, Yamada S, Go M, Yasuda S, <u>Toyoda H</u> , Usami E	Identifying risk factors of dose reduction or treatment discontinuation due to fatigue or gastrointestinal symptoms in patients receiving lenvatinib treatment for hepatocellular carcinoma.	J Oncol Pharm Pract			in press	
59)	Persano M, Casadei-Gardini A, Tada T, Suda G, Shimose S, Kudo M, Rossari F, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone MA, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Solda C, Sho T, Niizeki T, Nishida N, Steup C, Bruccoleri M, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Mascia L, Foti S, Camera S, Piscaglia F, Scartozzi M, Cascinu S, Rimini M	Lenvatinib versus sorafenib second-line therapy in patients with hepatocellular carcinoma progressed to atezolizumab plus bevacizumab: a retrospective real-world study.	Oncology			in press	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
60)	Sometani E, Hikita H, Murai K, <u>Toyoda H</u> , Tanaka S, Oze T, Sung J, Shimoda A, Fukuoka M, Shigeno S, Fukutomi K, Shirai K, Tahata Y, Saito Y, Nishio A, Furuta K, Kodama T, Sakamori R, Tatsumi T, Mita E, Umezawa A, Tanaka Y, Takehara T	High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogues.	Hepatol Res			in press	
61)	<u>Toyoda H</u> , Hiraoka A, Ochi H, Tsuji K, Tajiri K, Tani J, Tada T, Okubo T, <u>Atsukawa M</u> , Hirooka M, Itobayashi E, Hatanaka T, Kariyama K, Ishikawa T, Kuroda H, Takaguchi K, Kosaka H, Kawada K, Kakizaki S, Yada Y, Ogawa C, Nishimura T, Yasuda S, Deguchi A, Itokawa N, Arai T, Tsutsui A, Naganuma A, Enomoto H, Kaibori M, Nouse K, Hiasa Y, Kumada T, <u>Akita T</u> , <u>Tanaka J</u> , Johnson PJ	Prognostic significance of the BALAD serological model in systemic therapies for hepatocellular carcinoma: a personalized approach to the prediction of survival benefit.	JCO Clin Cancer Inform			in press	
62)	Kariyama K, Nouse K, Hiraoka A, <u>Toyoda H</u> , Tada T, Tsuji K, Ishikawa T, Hatanaka T, Itobayashi E, Takaguchi K, Tsutsui A, Naganuma A, Yasuda S, Kakizaki S, Wakuta A, Shiota S, Kumada T	Identification of high-risk group for diabetes mellitus-associated hepatocellular carcinoma using non-invasive test for liver fibrosis.	Eur J Gastroenterol Hepatol			in press	
63)	Naganuma A, Kakizaki S, Hatanaka T, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, <u>Toyoda H</u> , Koshiyama Y, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Matsui K, Yata Y, Tanaka H, Ohama H, Kuroda H, Matono T, Aoki T, Ochi H, Imai M, Nakamura S, Kanayama Y, Tanaka K, Tada F, Yoshida O, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T	Impact of time-of-day atezolizumab-bevacizumab combination therapy infusion for unresectable hepatocellular carcinoma: a retrospective multicenter study.	Hepatol Res			in press	
64)	Yasuda T, Ito T, Ishikawa T, Mizuno K, Yamamoto T, Yokoyama S, Yamamoto K, Imai N, Ishizu Y, Honda T, Koshiyama Y, Yasuda S, <u>Toyoda H</u> , Ando Y, Shimoyama Y, Kawashima H	Clinical features and pathological findings by liver biopsy in patients with immune-related sclerosing cholangitis induced by immune checkpoint inhibitors.	Dig Liver Dis			in press	
65)	Hiraoka A, Kudo M, Tada T, Hatanaka T, Kakizaki S, Kariyama K, Ohama H, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, <u>Toyoda H</u> , Matono T, Yata Y, Ogawa C, Naganuma A, Tani J, <u>Atsukawa M</u> , Nishimura T, Tajiri K, Kawata K, Kosaka H, Kuroda H, Hirooka M, Nishikawa H, Tada F, Nakamura S, Kanayama Y, Nouse K, Tanaka H, Tanaka K, Imai M, Tsutsui A, Nagano T, Aoki T, Koshiyama Y, Morishita A, Itokawa N, Okubo T, Arai T, Fukunishi S, Noritake H, Nakamura Y, Yoshida O, Enomoto H, Kaibori M, Hiasa Y, Kumada T	Tumor markers as biomarkers for evaluating and monitoring therapeutic efficacy in the era of immunotherapy: is alpha-fetoprotein alone sufficient?	Oncology			in press	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
66)	Matono T, Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tanaka K, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, <u>Toyoda H</u> , Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Tomomi Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Aoki T, Kuroda H, Yata Y, Nakamura Y, Yoshida O, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M	Survival outcomes associated with radiological progressive disease subtypes in patients with atezolizumab and bevacizumab-treated HCC.	J Gastroenterol Hepatol			in press	
67)	Kim M, Yoon EL, Park H, Ito T, Ishigami M, Jo AJ, Lee CM, Kang BK, Kim HL, Arai T, <u>Atsukawa M</u> , Kawanaka M, <u>Toyoda H</u> , Yu ML, Jun DW, Nguyen MH	Limited use of FIB-4 in with type 2 diabetes patients under 65 years of age.	Hepatol Res			in press	
68)	Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, <u>Toyoda H</u> , Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Matono T, Tanaka K, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kumada T	Reliable performance of mALBI grade-based risk models for predicting the prognosis of patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab as first-line treatment: comparative analysis of 13 risk models.	J Gastroenterol Hepatol			in press	
69)	Naganuma A, Kakizaki S, Hiraoka A, Tada T, Hatanaka T, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, <u>Toyoda H</u> , Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Hirooka M, Yata Y, Ohama H, Kuroda H, Matono T, Aoki T, Kanayama Y, Tanaka K, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T	Evaluation of treatment outcomes using dNLR and GNRI in combination therapy with atezolizumab and bevacizumab for hepatocellular carcinoma.	Cancer Med	14	e70618	2025	
70)	<u>Toyoda H</u>	Letter: Identifying the best model for predicting post-SVR HCC.	Aliment Pharmacol Ther	61	748-749	2025	○
71)	Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Tanaka H, Nishikawa H, Shibata H, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, Kumada T	Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib.	Sci Rep	15	72	2025	
72)	Shibata N, Ito T, Morita Y, <u>Toyoda H</u> , Kanzaki Y, Watanabe N, Yoshioka N, Miyazawa H, Shimojo K, Ohi T, Goto H, Karasawa H, Morishima I	Impact of the fibrosis-4 index in patients with ST-elevated myocardial infarction.	Coron Artery Dis	36	99-107	2025	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
73)	Siriwong N, Sriphoosanaphan S, Decharatanachart P, Yongpisarn T, Apiparakoon T, Tiyyarattanachai T, Kerr S, Treeprasertsuk S, Hagstrom H, Akbari C, Ekstedt M, Ito T, Ishigami M, <u>Toyoda H</u> , Hino K, Kawanaka M, Sumida Y, Seko Y, Peleg N, Shlomei A, Yip TCF, Wong GLH, Chaiteerakij R	Role of non-invasive tests on the prediction of hepatocellular carcinoma in non-alcoholic fatty liver disease patients without cirrhosis: a systematic review and meta-analysis of aggregate and individual patient data.	Eur J Gastroenterol Hepatol	37	358-369	2025	
74)	Hatanaka T, Saito N, Kakizaki S, Hiraoka A, Tada T, Kariyama K, Tani J, Takaguchi K, Itobayashi E, Ishikawa T, <u>Toyoda H</u> , Kawata K, Naganuma A, Yata Y, Ohama H, Matono T, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Nakamura S, Kumada T	Factors affecting an increase in spleen volume and association of spleen volume variation with the clinical outcomes of atezolizumab and bevacizumab treatment for hepatocellular carcinoma: a retrospective analysis.	Oncology	103	94-106	2025	
75)	Kim J, Ito T, Arai T, <u>Atsukawa M</u> , Kawanaka M, <u>Toyoda H</u> , Honda T, Yu ML, Yoon EL, Jun DW, Cha K, Nguyen MH	Modified FIB-4 index in type 2 diabetes mellitus with steatosis: a non-linear predictive model for advanced hepatic fibrosis.	Diagnostics	14	2500	2024	
76)	Hirano Y, Nouse K, Kariyama K, Hiraoka A, Shiota S, Wakuta A, Yasuda S, <u>Toyoda H</u> , Tsuji K, Hatanaka T, Kakizaki S, Naganuma A, Tada T, Itobayashi E, Ishikawa T, Shimada N, Takaguchi K, Tsutsui A, Nagano T, Imai M, Nakamura S, Kumada T	Prognostic efficacy of the albumin grade in patients with hepatocellular carcinoma	Acta Med Okayama	78	377-386	2024	
77)	Tada T, Kurosaki M, <u>Toyoda H</u> , Tamaki N, Yasui Y, Nakamura S, Mori N, Tsuji K, Ochi H, Akahane T, Kobashi H, Fujii H, Marusawa H, Kondo M, Urawa N, Yoshida H, Uchida Y, Morita A, Hasebe C, Mitsuda A, Ogawa C, Narita R, Kubotsu Y, Matsushita T, Shigeno M, Okamoto E, Okada K, Kasai T, Ishii T, Nonogi M, Yasuda S, Koshiyama Y, Kumada T, Izumi N	Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection who had received direct-acting antiviral therapy.	Liver Int	44	3060-3071	2024	○
78)	Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, <u>Toyoda H</u> , Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Matono T, Aoki T, Kanayama Y, Tanaka K, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T	Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: comparative analysis of conversion, partial response and complete response patients.	Aliment Pharmacol Ther	60	1361-1373	2024	
79)	Ishiba H, Fujii H, Kamada Y, Sumida Y, Takahashi H, Seko Y, <u>Toyoda H</u> , Hayashi H, Yamaguchi K, Iwaki M, Yoneda M, Arai T, Shima T, Morishita A, Kawata K, Tomita K, Kawanaka M, Yoshida Y, <u>Ikegami T</u> , Notsumata K, Oeda S, Fukushima H, Miyoshi E, Aishima S, Itoh Y, Okanoue T, Nakajima A.	Accuracy of type IV collagen 7S versus Enhanced Liver Fibrosis score for diagnosing fibrosis in patients with metabolic dysfunction-associated steatotic liver disease.	Hepatol Commun	9	e0563	2024	
80)	Umezui T, Mori T, <u>Toyoda H</u> , Kanekura K, Tamori A, Ochiya T, Kuroda M, Akutsu T, Murakami Y	Analysis of carcinogenic involvement of miRNA pattern in peripheral non-cancerous tissues and chronic viral liver injury.	Int J Mol Sci	25	7858	2024	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
81)	Shibata N, Morita Y, Ito T, Kanzaki Y, Watanabe N, Yoshioka N, Arao Y, Yasuda S, Koshiyama Y, <u>Toyoda H</u> , Morishima I	A machine learning algorithm for stratification of risk of cardiovascular disease in metabolic dysfunction-associated steatotic liver disease.	Eur J Intern Med	129	62-70	2024	
82)	Ji F, Tran S, Ogawa E, Huang CF, Suzuki T, Wong YJ, <u>Toyoda H</u> , Jun DW, Li L, Uojima H, Nozaki A, Chuma M, Tseng CH, Hsu YC, Ishigami M, Honda T, <u>Atsukawa M</u> , Haga H, Enomoto M, Trinh H, Preda CM, Vutien P, Landis C, Lee DH, Watanabe T, Takahashi H, Abe H, Asai A, Eguchi Y, Li J, Wang X, Li J, Liu J, Liang J, Lam CPM, Huang R, Ye Q, Pan H, Zhang J, Cai D, Wang Q, Huang DQ, Wong G, Wong VWS, Li J, Do S, Furusyo N, Nakamuta M, Nomura H, Kajiwarra E, Yoon EL, Ahn SB, Azuma K, Dohmen K, An J, Song DS, Cho HC, Kawano A, Koyanagi T, Ooho A, Satoh T, Takahashi K, Yeh ML, Tsai PC, Yasuda S, Zhao Y, Liu Y, Okubo T, Itokawa N, Jun MJ, Ishikawa T, Takaguchi K, Senoh T, Zhang M, Zhao C, Alecu RI, Tay WX, Devan P, Liu JK, Kozuka R, Vargas-Accarino E, Do AT, Maeda M, Chuang WL, Huang JF, Dai CY, Cheung R, Buti M, Niu J, Xie W, Ren H, Lim SG, Wu C, Yuen MF, Shang J, Zhu Q, Ueno Y, Tanaka Y, Hayashi J, Yu ML, Nguyen MH	Real-world effectiveness and tolerability of interferon-free direct-acting antiviral for 15,849 patients with chronic hepatitis C: a multinational cohort study.	J Clin Transl Hepatol	12	646-658	2024	
83)	Miyamoto H, Kondo Y, Itobayashi E, Uehara M, Hiraoka A, Kudo M, Kakizaki S, Kagawa T, Miuma S, Suzuki T, Sugi K, Suyama K, Beppu T, <u>Toyoda H</u> , Yoshiji H, Uojima H, Miyase S, Inoue K, Tamori A, Ito T, Shimose S, Suda G, Hayashi T, Onishi M, Narahara S, Watanabe T, Iwatsuki M, Fukushima S, Tanaka Y	Evaluation of the associations of IL7 genetic variants with toxicity and efficacy of immune checkpoint inhibitors: a replication study of a Japanese population, based on the findings of a Caucasian genome-wide association study.	Hepatol Res	54	1215-1225	2024	
84)	Kimura M, Yamada S, Go M, Yasuda S, <u>Toyoda H</u> , Usami E	Safety evaluation of lenvatinib treatment after atezolizumab plus bevacizumab therapy for patients with unresectable liver cancer: a comparison of lenvatinib as 1st or 2nd line treatment.	Oncol Lett	28	330	2024	
85)	Kumazaki S, Hikita H, Tahata Y, Sung JH, Fukumoto K, Myojin Y, Sakane S, Murai K, Sasaki Y, Shirai K, Saito Y, Kodama T, Kakita N, Takahashi H, <u>Toyoda H</u> , Suda G, Morii E, Kojima T, Ebihara T, Shimizu K, Sasaki Y, Tatsumi T, Takehara T	Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis.	Aliment Pharmacol Ther	60	327-339	2024	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
86)	Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Rossari F, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone MA, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Solda C, Sho T, Niizeki T, Nishida N, Steup C, Bruccoleri M, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Foti S, Camera S, Piscaglia F, Scartozzi M, Cascinu S, Casadei-Gardini A	Adverse events as potential predictive factors of activity in patients with advanced HCC treated with atezolizumab plus bevacizumab.	Target Oncol	19	645-659	2024	
87)	Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, <u>Toyoda H</u> , Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouse N, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Matono T, Aoki T, Kuroda H, Yata Y, Koizumi Y, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M	Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.	Aliment Pharmacol Ther	60	233-245	2024	
88)	<u>Atsukawa M</u> , Tsubota A, Kondo C, <u>Toyoda H</u> , Takaguchi K, Nakamura M, Watanabe T, Morishita A, Tani J, Okubo H, Hiraoka A, Nozaki A, Chuma M, Kawata K, Uojima H, Ogawa C, Asano T, Mikami S, Kato K, Matsuura K, <u>Ikegami T</u> , Ishikawa T, Tsuji K, Tada T, Tsutsui A, Senoh T, Kitamura M, Okubo T, Arai T, Fukunishi S, Kohjima M, Akahane T, Nishikawa H, Iwasa M, Tanaka Y, Iwakiri K	ALBI score predicts morphological changes in esophageal varices following direct-acting antiviral-induced sustained virological response in patients with liver cirrhosis.	J Gastroenterol	59	709-718	2024	○
89)	Sumida Y, <u>Toyoda H</u> , Yasuda S, Kimoto S, Sakamoto K, Nakade Y, Ito K, Osonoi T, Yoneda M	Comparison of efficacy between pemafibrate and omega-3-acid ethyl ester in the liver: the PORTRAIT study.	J Atheroscler Thromb	31	1620-1633	2024	
90)	Itokawa N, <u>Atsukawa M</u> , Tsubota A, Ishikawa T, <u>Toyoda H</u> , Takaguchi K, Watanabe T, Ogawa C, Hiraoka A, Okubo H, Uojima H, Chuma M, Nozaki A, Kato K, Mikami S, Tani J, Morishita A, Tada T, Asano T, Senoh T, Oikawa T, Okubo T, Kumada T, Iwakiri K	Kinetics of the hepatitis B core-related antigen and treatment responses in chronic hepatitis B patients treated with tenofovir alafenamide.	Hepatol Res	54	993-1003	2024	
91)	Sasaki K, Kawamura Y, Ogawa C, Yabushita K, Watanabe S, Hayashi H, Kochi T, Tomonari T, Ninomiya M, Takai K, Imajo K, Ito T, Kita R, Mawatari S, <u>Nishina S</u> , <u>Toyoda H</u>	Skill proficiency, efficacy, and safety of the transradial approach in transarterial treatments for hepatocellular carcinoma.	Cureus	16	e57800	2024	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
92)	Chuma M, Uojima H, <u>Toyoda H</u> , Hiraoka A, Arase Y, <u>Atsukawa M</u> , Itokawa N, Okubo T, Tada T, Numata K, Morimoto M, Sugimori M, Nozaki A, Iwasaki S, Yasuda S, Koshiyama Y, Mishima Y, Tsuruya K, Tokoro C, Miura Y, Hidaka H, Kumada T, Kusano C, Kagawa T, Maeda S	Clinical significance of circulating biomarkers of immune checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma.	Hepatol Int	18	1472-1485	2024	
93)	Tsutsumi T, Kawaguchi T, Fujii H, Kamada Y, Takahashi H, Kawanaka M, Sumida Y, Iwaki M, Hayashi H, <u>Toyoda H</u> , Oeda S, Hyogo H, Morishita A, Munekage K, Kawata K, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Ueda S, Aishima S, Nakajima A, Okanoue T.	Hepatic inflammation and fibrosis are profiles related to mid-term mortality in biopsy-proven MASLD: a multicenter study in Japan.	Aliment Pharmacol Ther	59	1559-1570	2024	
94)	Shibata N, Ito T, <u>Toyoda H</u> , Tanaka A, Morita Y, Kanzaki Y, Watanabe N, Yoshioka N, Yasuda S, Morishima I.	Predictability of noninvasive liver fibrosis score for cardiac events in patients with nonalcoholic fatty liver disease.	Nutr Metab Cardiovasc Dis	34	2115-2123	2024	
95)	Sakata T, Yoshio S, Yamazoe T, Mori T, Kakazu E, Aoki Y, Aoyanagi N, Okamoto T, Ito T, <u>Toyoda H</u> , Kawaguchi T, Ono Y, Takahashi Y, Taketomi A, Kanto T	Immunoglobulin-like transcript 2 as an impaired anti-tumor cytotoxicity marker of natural killer cells in patients with hepatocellular carcinoma.	Front Immunol	15	1389411	2024	
96)	Ohama H, Hiraoka A, Tada T, Kariyama K, Itobayashi E, Tsuji K, Ishikawa T, <u>Toyoda H</u> , Hatanaka T, Kakizaki S, Naganuma A, Tada F, Tanaka H, Nakamura S, Nouse K, Tanaka K, Kumada T	Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct-acting antiviral agents.	J Gastroenterol Hepatol	39	1394-1402	2024	
97)	Uojima H, Yamasaki K, Sugiyama M, Kage M, Ishii N, Shirabe K, Hidaka H, Kusano C, Murakawa M, Asahina Y, Nishimura T, Iijima H, Sakamoto K, Ito K, Amano K, Kawaguchi T, Tamaki N, Kurosaki M, Suzuki T, Matsuura K, Taketomi A, Joshita S, Umemura T, <u>Nishina S</u> , Hino K, <u>Toyoda H</u> , Yatsuhashi H, Mizokam M.	Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation.	J Gastroenterol	59	598-608	2024	
98)	Kariyama K, Nouse K, Kawanaka M, Fujii H, <u>Toyoda H</u> , Iwaki M, Hayashi H, Oeda S, Hyogo H, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Kumada T, Okanoue T.	Validation study of age-independent fibrosis score (Fibrosis-3 index) in patients with metabolic dysfunction-associated steatotic liver disease.	Hepatol Res	54	912-920	2024	
99)	Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Hatanaka T, Tani J, Takaguchi K, <u>Atsukawa M</u> , Itobayashi E, Nishimura T, Tsuji K, Tajiri K, Ishikawa T, Yasuda S, <u>Toyoda H</u> , Fukunishi S, Ogawa C, Kakizaki S, Shimada N, Naganuma A, Kawata K, Kosaka H, Kuroda H, Matono T, Yata Y, Ochi H, Tada F, Nouse K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Yokohama K, Nishikawa H, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, Kumada T	Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma.	Cancer Rep	7	e2042	2024	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
100)	Kimura M, Yamada S, Go M, Yasuda S, <u>Toyoda H</u> , Usami E.	Evaluation of atezolizumab plus bevacizumab versus modified lenvatinib therapy in Child-Pugh A unresectable hepatocellular carcinoma.	Cancer Diagn Progn	4	122-128	2024	
101)	Hirooka M, Ogawa S, Koizumi Y, Yoshida Y, Goto T, Yasuda S, Yamahira M, Tamai T, Kuromatsu R, Matsuzaki T, Suehiro T, Kamada Y, Sumida Y, Hiasa Y, <u>Toyoda H</u> , Kumada T.	iATT liver fat quantification for steatosis grading by referring to MRI proton density fat fraction: a multicenter study.	J Gastroenterol	59	504-514	2024	
102)	Sakane S, Hikita H, Shirai K, Sakamoto T, Narumi R, Adachi J, Kakita N, Yamada Y, <u>Toyoda H</u> , Takahashi H, Suda G, Kai M, Tahata Y, Sakamori R, Kumazaki S, Fukumoto K, Myojin Y, Murai K, Kodama T, Tatsumi T, Tomonaga T, Sakamoto N, Morii E, Takehara T.	Proteomic analysis of serum extracellular vesicles reveals Fibulin-3 as a new marker predicting liver-related events in MASLD.	Hepatol Commun	8	e0448	2024	
103)	Jang TY, Liang PC, Jun DW, Jung JH, <u>Toyoda H</u> , Wang CW, Yuen MF, Cheung KS, Yasuda S, Kim SE, Yoon EL, An J, Enomoto M, Kozuka R, Chuma M, Nozaki A, Ishikawa T, Watanabe T, <u>Atsukawa M</u> , Arai T, Hayama K, Ishigami M, Cho YK, Ogawa E, Kim HS, Shim JJ, Uojima H, Jeong SW, Ahn SB, Takaguchi K, Senoh T, Buti M, Vargas-Accarino E, Abe H, Takahashi H, Inoue K, Yeh ML, Dai CY, Huang JF, Huang CF, Chuang WL, Nguyen MH, Yu ML.	Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: a multinational study.	J Gastroenterol Hepatol	39	1190-1197	2024	
104)	Kudaravalli S, Huang DQ, Yeh ML, Trinh L, Tsai PC, Hsu YC, Kam LY, Nguyen VH, Ogawa E, Lee DH, Ito T, Watanabe T, Enomoto M, Preda CM, Ko MKL, Hui RWH, <u>Atsukawa M</u> , Suzuki T, Marciano S, Barreira A, Do S, Uojima H, Takahashi H, Quek SXZ, Khine HHTW, Ishigami M, Itokawa N, Go MS, Kozuka R, Marin RI, Sandra I, Li J, Zhang JQ, Wong C, Yoshimaru Y, Vo DKH, Tseng CH, Lee CJ, Inoue K, Maeda M, Hoang JK, Chau A, Chuang WL, Dai CY, Huang JF, Huang CF, Buti M, Tanaka Y, Gadano AC, Yuen MF, Cheung R, Lim SG, Trinh HN, <u>Toyoda H</u> , Yu ML, Nguyen MH	Sex and ethnic disparities in hepatitis B evaluation and treatment: a real-world study from both East and West.	J Hepatol	81	33-41	2024	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
105)	Rimini M, Stefanini B, Tada T, Suda G, Shimose S, Kudo M, Finkelmeier F, Yoo C, Presa J, Amadeo E, Genovesi V, De Grandis MC, Iavarone M, Marra F, Foschi F, Tamburini E, Rossari F, Vitiello F, Bartalini L, Solda C, Tovoli F, Vivaldi C, Lonardi S, Silletta M, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Himmelsbach V, Montes M, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Camera S, Foti S, Aldrighetti L, Cascinu S, Casadei-Gardini A, Piscaglia F	Impact of body mass index on the prognosis of unresectable HCC patients receiving first line lenvatinib or atezolizumab plus bevacizumab.	Liver Int	44	1108-1125	2024	
106)	Tada T, Kumada T, Hiraoka A, Kariyama K, Yasuda S, Tada F, Ohama H, Nouse K, Matono T, Nakamura S, <u>Toyoda H</u>	mADRES predicts hepatocellular carcinoma development in patients with hepatitis C virus who achieved sustained virological response.	J Gastroenterol Hepatol	39	1164-1171	2024	
107)	Iwaki M, Fujii H, Hayashi H, <u>Toyoda H</u> , Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)	Prognosis of biopsy-confirmed MASLD: a sub-analysis of the CLIONE study.	Clin Mol Hepatol	30	225-234	2024	
108)	Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Solda C, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Foti S, Camera S, Stefanini B, Scartozzi M, Cascinu S, Casadei-Gardini A, Rimini	Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a real-world, multicenter study.	Liver Cancer	13	522-536	2024	
109)	Kariyama K, Nouse K, Hiraoka A, <u>Toyoda H</u> , Tada T, Tsuji K, Ishikawa T, Hatanaka T, Itobayashi E, Takaguchi K, Tsutsui A, Naganuma A, Yasuda S, Kakizaki S, Wakuta A, Shiota S, Kudo M, Kumada T	Treatment options for solitary hepatocellular carcinoma ≤5 cm: surgery vs ablation: a multicenter retrospective study.	J Liver Cancer	24	71-80	2024	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
110)	Johnson PJ, Kalyuzhnyy A, Boswell E, <u>Toyoda H</u>	Progression of chronic liver disease to hepatocellular carcinoma: implications for surveillance and management.	BJC Rep	2	39	2024	
111)	Johnson PJ, Bhatti E, <u>Toyoda H</u> , He S	Serological detection of HCC in full-application of machine learning and implications for the diagnostic models.	JCO Clin Cancer Inform	8	e2300119	2024	○
112)	Park JE, Nguyen VH, Tsai PC, <u>Toyoda H</u> , Leong J, Dr. Guy JE, Yeh ML, Huang CF, Yasuda S, Abe H, Hsu YC, Tseng CH, Liu J, Chen YL, Lin PY, Jun DW, Yoshimaru Y, Ogawa E, Ishigami M, Enomoto M, Tamori A, Uojima H, Wang XZ, Xu Q, Takahashi H, Eguchi Y, Inoue K, Huang DQ, Zhao WJ, Chuang WL, Dai CY, Huang JF, Barnett S, Maeda M, Cheung R, Landis C, Tanaka Y, Roberts LR, Schwartz ME, Kumada T, Yu ML, Nguyen MH.	Racial and ethnic disparities in untreated patients with hepatitis C virus-related hepatocellular carcinoma but not in those with sustained virologic response.	Aliment Pharmacol Ther	59	742-751	2024	
113)	Camera S, Rimini M, Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Salani F, Marsegli M, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Lonardi S, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Foti S, Piscaglia F, Scartozzi M, Cascinu S, Casadei-Gardini A	Safety and efficacy of lenvatinib in very elderly patients with unresectable hepatocellular carcinoma.	Target Oncol	19	29-39	2024	
114)	Arai T, Takahashi H, Seko Y, <u>Toyoda H</u> , Hayashi H, Yamaguchi K, Iwaki M, Yoneda M, Shima T, Fujii H, Morishita A, Kawata K, Tomita K, Kawanaka M, Yoshida Y, <u>Ikegami T</u> , Notsumata K, Oeda S, <u>Atsukawa M</u> , Kamada Y, Sumida Y, Fukushima H, Miyoshi E, Aishima S, Okanoue T, Itoh Y, Nakajima A, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD).	Accuracy of the enhanced liver fibrosis test in patients with type 2 diabetes mellitus and its clinical implications.	Clin Gastroenterol Hepatol	22	789-797	2024	
115)	Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Yokohama K, Nishikawa H, Nishimura T, Shimada N, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Aoki T, Tanaka K, Tanaka T, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kudo M, Kumada T.	Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: a multicenter study.	Hepatol Res	54	382-391	2024	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
116)	Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Solda C, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Burgio V, Piscaglia F, Scartozzi M, Cascinu S, Casadei-Gardini A, Rimini M	Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real life worldwide population.	Int J Cancer	154	1043-1056	2024	
117)	Huang DQ, Hoang JK, Kamal R, Tsai PC, <u>Toyoda H</u> , Yeh ML, Yasuda S, Leong J, Maeda M, Huang CF, Jun DW, Ishigami M, Tanaka Y, Uojima H, Ogawa E, Abe H, Hsu YC, Tseng CH, Alsudaney M, Yang JD, Yoshimaru Y, Suzuki T, Liu JK, Landis C, Dai CY, Huang JF, Chuang WL, Schwartz M, Dan YY, Esquivel C, Bonham A, Yu ML, Nguyen MH.	Antiviral therapy utilization and 10-year outcomes in resected HBV- and HCV-related hepatocellular carcinoma.	J Clin Oncol	42	790-799	2024	○
118)	Ogawa E, Jun DW, <u>Toyoda H</u> , Hsu YC, Yoon EL, Ahn SB, Yeh ML, Do S, Trinh HM, Takahashi H, Enomoto M, Kawada N, Yasuda S, Tseng CH, Kawashima K, Lee HA, Inoue K, Haga H, Do AT, Maeda M, Hoang JH, Cheung R, Ueno Y, Eguchi Y, Furusyo N, Yu ML, Tanaka Y, Nguyen MH	Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide: a prospective, multinational study.	Aliment Pharmacol Ther	59	239-248	2024	
119)	Jang TY, Liang PC, Jun DW, Jung JH, <u>Toyoda H</u> , Wang CW, Yuen MF, Cheung KS, Yasuda S, Kim SE, Yoon E, An J, Enomoto M, Kozuka R, Chuma M, Nozaki A, Ishikawa T, Watanabe T, <u>Atsukawa M</u> , Arai T, Hayama K, Ishigami M, Cho YK, Ogawa E, Kim HS, Shim JJ, Uojima H, Jeong SW, Ahn SB, Takaguchi K, Senoh T, Buti M, Vargas-Accarino E, Abe H, Takahashi H, Inoue K, Yeh ML, Dai CY, Huang JF, Huang CF, Chuang WL, Nguyen MH, Yu ML	Pre-treatment gamma-glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogs.	Kaohsiung J Med Sci	40	188-197	2024	
120)	Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Matono T, Aoki T, Kuroda H, Yata Y, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kudo M	Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.	Liver Int	44	113-124	2024	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
121)	Toyoda H , Kikuchi K	Author response to management of dialysis patients with hepatitis C virus in the era of direct-acting antiviral therapy.	Ther Apher Dial	28	160-161	2024	○
122)	Endo K, Kakisaka K, Abe T, Yusa K, Nakaya I, Watanabe T, Suzuki A, Yoshida Y, Oikawa T, Miyasaka A , Kuroda H, Matsumoto T	Positive impact of obesity on the prognosis of liver cirrhosis	J Gastroenterol Hepatol.	39	1663-1672	2024	
123)	Endo K, Kakisaka K, Abe T, Yusa K, Nakaya I, Watanabe T, Abe H, Suzuki A, Yoshida Y, Oikawa T, Miyasaka A , Kuroda H, Matsumoto T	Grip strength complements performance status in assessing general condition in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab	Hepatol Res.	54	1158-1173	2024	
124)	Sasaki T, Kakisaka K, Miyasaka A , Nishiya M, Yanagawa N, Kuroda H, Matsumoto T, Takahashi M, Okamoto H	Spontaneous reactivation of hepatitis B virus with multiple novel mutations in an elderly patient with resolved hepatitis B virus infection	Clin J Gastroenterol.	17	638-690	2024	
125)	Nio K, Shimakami T , Terashima T, Yanagi M, Toyama T, Koshikawa N, Nakagawa M, Yoshida E, Yoshimura T, Seiki M, Honda M, Yamashita T.	Serum laminin $\gamma 2$ monomer as a predictive biomarker for hepatocellular carcinoma in patients with chronic hepatitis B virus infection: a retrospective cohort study.	Scientific Reports	14(1)	25395	2024	
126)	Murayama A, Igarashi H, Yamada N, Aly HH, Toyama M, Isogawa M, Shimakami T , Kato T.	Exploring the tolerable region for HiBiT tag insertion in the hepatitis B virus genome.	mSphere	9(10)	e0051824	2024	
127)	Yoshita M, Funaki M, Shimakami T , Kakuya M, Murai K, Sugimoto S, Kawase S, Matsumori K, Kawane T, Nishikawa T, Nakamura A, Suzuki R, Ishida A, Kawasaki N, Sato Y, Li YY, Sumiyadorj A, Nio K, Takatori H, Kawaguchi K, Kuroki K, Kato T, Honda M, Yamashita T.	High-Throughput Screening of Antiviral Compounds Using a Recombinant Hepatitis B Virus and Identification of a Possible Infection Inhibitor, Skimmiannine.	Viruses	16(8)	1346	2024	
128)	Okada H, Sakamoto T, Nio K, Li Y, Kuroki K, Sugimoto S, Shimakami T , Doi N, Honda M, Seiki M, Kaneko S, Yamashita T.	Lipid nanoparticle-encapsulated DOCK11-siRNA efficiently reduces hepatitis B virus cccDNA level in infected mice.	Molecular Therapy - Methods & Clinical Development	32(3)	101289	2024	
129)	Miura M, Nishino M, Kawaguchi K, Li S, Shimakami T , Tamai T, Nakagawa H, Terashima T, Iida N, Takatori H, Arai K, Sakai Y, Yamashita T, Honda M, Kaneko S, Mizukoshi E, Yamashita T.	Programmed cell death-1 is involved with peripheral blood immune cell profiles in patients with hepatitis C virus antiviral therapy.	PLoS One	19(5)	e0299424	2024	
130)	Lyu J, Okada H, Sunagozaka H, Kawaguchi K, Shimakami T , Nio K, Murai K, Shirasaki T, Yoshida M, Arai K, Yamashita T, Tanaka T, Harada K, Takamura T, Kaneko S, Yamashita T, Honda M.	Potential utility of l-carnitine for preventing liver tumors derived from metabolic dysfunction-associated steatohepatitis.	Hepatology Communications	8(5)	e0425	2024	
131)	Shimizu R, Murai K, Tanaka K, Sato Y, Takeda N, Nakasyo S, Shirasaki T, Kawaguchi K, Shimakami T , Nio K, Nakaya Y, Kagiwada H, Horimoto K, Mizokami M, Kaneko S, Murata K, Yamashita T, Honda M.	Nucleos(t)ide analogs for hepatitis B virus infection differentially regulate the growth factor signaling in hepatocytes	Hepatology Communications	8(1)	e0351	2024	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
132)	Murakami M, Fujii N, Kanda E, <u>Kikuchi K</u> , et al	Association between Timing of Vascular Access Creation and Mortality in Patients Initiating Hemodialysis: A Nationwide Cohort Study in Japan	Am J Nephrol	55(6)	647-656	2024	
133)	Yoshifuji A, Toda M, Oyama E, Nakayama T, Mise-Omata S, <u>Kikuchi K</u> , et al	Cellular and humoral immune responses to COVID-19 booster vaccination in Japanese dialysis patients	Clin Exp Nephro	28(7)	674-682	2024	
134)	Sugawara Y, Iwagami M, <u>Kikuchi K</u> , et al	Coronavirus disease 2019 vaccination effectiveness based on the 2021 Japanese dialysis registry.	Nephrology (Carlton)	29(10)	671-679	2024	
135)	Abe M, <u>Kikuchi K</u> , et al	Intermittent infusion hemodiafiltration is associated with improved survival compared to hemodialysis	Renal Replacement Therapy	10	https://rrtjournal.biomedcentral.com/articles/10.1186/s41100-024-00540-4	2024	
136)	Abe M, <u>Kikuchi K</u> , et al	Current dialyzer classification in Japan and mortality risk in patients undergoing hemodialysis	Sci Rep	14(1)	doi: 10.1038/s41598-024-60831-y	2024	
137)	岩本淳一, 門馬匡邦, 玉虫惇, 上田元, 中川俊一郎, 森山由貴, 小西直樹, 屋良昭一郎, 宮崎照雄, 平山剛, 池上正, 本多彰.	長期経口摂取困難例および炎症性腸疾患でのカルニチン欠乏に関する検討	消化と吸収	47(1)	53	2024	
138)	宮崎照雄, 上田元, <u>池上正</u> , 本多彰.	胆汁酸によるタウリンの動態制御の雌雄差-胆汁酸ヒト化マウスを用いた検討	タウリンリサーチ	10(1)	8-12	2024	
139)	門馬匡邦, 岩本淳一, 玉虫惇, 上田元, 小西直樹, 屋良昭一郎, 宮崎照雄, 池上正, 本多彰.	血中胆汁酸分析を用いた dysbiosis の評価	消化と吸収	46(2)	155-8	2024	
140)	Ueda H, Honda A, Miyazaki T, Morishita Y, Hirayama T, Iwamoto J, <u>Ikegami T</u> .	High-fat/high-sucrose diet results in a high rate of MASH with HCC in a mouse model of human-like bile acid composition.	Hepatol Commun	9(1)	e0606	2024	○
141)	Sasaki K, Kawanaka M, Tomiyama Y, Takaki A, Otsuka M, Ikeda F, Yoshioka N, Kaneto H, Wada J, Fukuda T, Hino K, <u>Nishina S</u> .	Characteristics of diabetes mellitus patients with nonviral chronic liver disease who developed hepatocellular carcinoma.	Hepatol Res			in press	○
142)	Miwa T, Hanai T, Hirata S, Nishimura K, Sahashi Y, Unome S, Imai K, Shirakami Y, Suetsugu A, Takai K, <u>Shimizu M</u> .	Vitamin D deficiency stratifies the risk of covert and overt hepatic encephalopathy in patients with cirrhosis: A retrospective cohort study.	Clin Nutr ESPEN	63	267-273	2024	○
143)	Miwa T, Hanai T, Hayashi I, Hirata S, Nishimura K, Unome S, Nakahata Y, Imai K, Shirakami Y, Suetsugu A, Takai K, <u>Shimizu M</u> .	Dysphagia risk evaluated by the Eating Assessment Tool-10 is associated with health-related quality of life in patients with chronic liver disease.	Nutrition	124	112440	2024	○
144)	Miwa T, Hanai T, Hirata S, Nishimura K, Unome S, Nakahata Y, Imai K, Shirakami Y, Suetsugu A, Takai K, <u>Shimizu M</u> .	Animal naming test stratifies the risk of falls and fall-related fractures in patients with cirrhosis.	Sci Rep	14	4307	2024	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
145)	Miwa T, Richardson JK, Murphy SL, Ellmers TJ, Miwa Y, Maeda T, Hanai T, <u>Shimizu M.</u>	Short-latency reaction time and accuracy are impaired in patients with cirrhosis: An international multicenter retrospective study.	Geriatr Gerontol Int	24	25-31	2024	○
146)	Miwa T, Utakata Y, Hanai T, Aiba M, Unome S, Imai K, Takai K, Shiraki M, Katsumura N, <u>Shimizu M.</u>	Acute kidney injury development is associated with mortality in Japanese patients with cirrhosis: Impact of amino acid imbalance.	J Gastroenterol	59	849-857	2024	○
147)	Hanai T, Nishimura K, Unome S, Miwa T, Nakahata Y, Imai K, Suetsugu A, Takai K, <u>Shimizu M.</u>	Alcohol-associated liver disease increases the risk of muscle loss and mortality in patients with cirrhosis.	J Gastroenterol	59	932-940	2024	○
148)	Hanai T, Nishimura K, Unome S, Miwa T, Nakahata Y, Imai K, Suetsugu A, Takai K, <u>Shimizu M.</u>	Nutritional counseling improves mortality and prevents hepatic encephalopathy in patients with alcohol-associated liver disease.	Hepatol Res	54	1089-1098	2024	○
149)	Hanai T, Nishimura K, Unome S, Miwa T, Nakahata Y, Imai K, Suetsugu A, Takai K, <u>Shimizu M.</u>	A survey questionnaire evaluating physical activity patterns and determinants in patients with chronic liver disease.	J Gastroenterol	59	45-55	2024	○
150)	Imai K, Takai K, Aiba M, Unome S, Miwa T, Hanai T, Suetsugu A, <u>Shimizu M.</u>	Adverse events in targeted therapy for unresectable hepatocellular carcinoma predict clinical outcomes.	Cancers	16	3150	2024	
151)	Imai K, Takai K, Unome S, Miwa T, Hanai T, Suetsugu A, <u>Shimizu M.</u>	Lenvatinib exacerbates the decrease in skeletal muscle mass in patients with hepatocellular carcinoma, whereas atezolizumab plus bevacizumab does not.	Cancers	16	442	2024	

令和 5(2023)年度 研究成果の刊行に関する一覧表 【書籍】

	著者氏名	論文タイトル名	書籍全体の 編集者名	書籍名	出版社名	出版地	出版年	ページ	関連
1)	秋田智之、田中純子	日本における C 型肝炎の疫学 ー国際比較ー		日本臨床 増刊号 ウイルス性肝炎学 2023	日本臨床社	東京	2023	91-99	○
2)	相崎英樹、溝上雅史、脇田隆字	ウイルス性肝炎発見の歴史		日本臨床 増刊号 ウイルス性肝炎学 2023	日本臨床社	東京	2023	7-11	
3)	保坂哲也	核酸アナログ製剤治療による HBs 抗原陰性化と発癌		日本臨床 増刊号 ウイルス性肝炎学 2023	日本臨床社	東京	2023	345	○
4)	保坂哲也	発癌高リスク群の設定、B 型慢性肝炎	佐藤雅哉	臨床検査 10 月・増大号「肝疾患臨床検査でどう迫る？」	医学書院	東京	2023	1122	○
5)	保坂哲也	B 型慢性肝炎の薬物療法	臨床消化器内科編集委員会	臨床消化器内科 6 月増刊号「肝疾患、診療のチェックポイント 2023」	日本メディカルセンター	東京	2023	160	○
6)	遠藤啓、柿坂啓介、宮坂昭生、黒田英克、松本主之	当科における肝硬変の成因別実態	榎本平之 芥田憲夫 疋田隼人	肝硬変の成因別実態 2023	文光堂	東京	2024 年	33-34	○
7)	菊地勘	透析医療における標準的な透析操作と感染予防に関するガイドライン（六訂版）	日本透析医会	透析医療における標準的な透析操作と感染予防に関するガイドライン（六訂版）	日本透析医会	東京	2023	1-146	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
1)	Setoyama H, Nishida N, Nagashima S, Ko K, Yamazoe T, Tanaka Y, Mizokami M, <u>Tanaka J</u> , Kanto T	Prevalence of fatty liver and advanced fibrosis by ultrasonography and FibroScan in a general population random sample	Hepatology Research	52	1147-1155	2023	○
2)	Takemoto Y, Tanimine N, Yoshinaka H, Tanaka Y, Takafuta T, <u>Sugiyama A</u> , <u>Tanaka J</u> , Ohdan H	Multi-phasic gene profiling using candidate gene approach predict the capacity of specific antibody production and maintenance following COVID-19 vaccination in Japanese population	Frontiers in Immunology	14	1217206	2023	
3)	Omori K, Shigemoto N, Kitagawa H, Nomura T, Kaiki Y, Miyaji K, <u>Akita T</u> , Kobayashi T, Hattori M, Hasunuma N, <u>Tanaka J</u> , Ohge H	Virtual reality as a learning tool for improving infection control procedures	American Journal of Infection Control	51(2)	129	2023	
4)	Ko K, Takahashi K, Ito N, <u>Sugiyama A</u> , Nagashima S, Miwata K, Kitahara Y, Okimoto M, Ouoba O, Golda Akuffo GA, E B, <u>Akita T</u> , Takafuta T, <u>Tanaka J</u>	Despite low viral titer in saliva samples, Sanger-based SARS-CoV-2 spike gene sequencing is highly applicable for the variant identification	BMC Medical Genomics	16(1)	199	2023	
5)	Saito E, Tanaka S, Abe S, Hirayabashi M, Ishihara J, Katanoda K, Lin Y, Nagata C, Sawada N, Takachi R, Goto A, <u>Tanaka J</u> , Ueda K, Hori M, Matsuda T, Inoue M	Economic burden of cancer attributable to modifiable risk factors in Japan	Global Health & Medicine	5(4)	238-245	2023	○
6)	Hussain Md RA, Ali Mohammad, <u>Sugiyama A</u> , Hiebert L, Rahman M. A, Azam G, Ouoba S, E B, Ko K, <u>Akita T</u> , W. Ward J, <u>Tanaka J</u>	The impact of COVID-19 on hepatitis B and C virus prevention, diagnosis, and treatment in Bangladesh compared with Japan and the global perspective	BMC Health Services Research	23(1137)	1	2023	
7)	Ouoba S, Ko K, Lingani M, Nagashima S, Guingané A N, E Bunthen, Hussain Md RA, <u>Sugiyama Aya</u> , <u>Akita T</u> , Ohisa M, Sanou M A, Traore O, Nassa J W, Sanou M, Takahashi K, Halidou T, <u>Junko T</u>	Intermediate hepatitis B virus infection prevalence among 1622 pregnant women in rural Burkina Faso and implications for mother-to-child transmission	Scientific Reports	13(1)	6115	2023	○
8)	E Bunthen, Ko K, Kim R, Nagashima S, Ouoba S, Hussain Md RA, Sato T, Chuon C, Abe K, <u>Sugiyama A</u> , Takahashi K, <u>Akita T</u> , Tung R, Ork V, Hossain Md S, Saphonn V, <u>Tanaka J</u>	Residual risk of mother-to-child transmission of HBV despite timely Hepatitis B vaccination: a major challenge to eliminate hepatitis B infection in Cambodia	BMC	23(1)	261	2023	○
9)	Basirat Mojisola Lawal-Ayinde, Morita T, Oda K, Nazmul T, Kurose M, Nomura T, Yamamoto A, Higashiura A, <u>Akita T</u> , <u>Tanaka J</u> , Horiuchi I, Goda H, Sakaguchi T	Virus purification highlights the high susceptibility of SARS-CoV-2 to a chlorine-based disinfectant, chlorous acid.	PLOS ONE	18(7)	e0288634	2023	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
10)	Polaris Observatory Collaborators Homie A. Razavi, Maria Buti, Norah A. Terrault, Stefan Zeuzem, Cihan Yurdaydin, <u>Junko Tanaka</u> , Alessio Aghemo, Ulus S. Akarca, Nasser M Al Masri, Abduljaleel M. Alalwan, Soo Aleman, Abdullah S. Alghamdi, Saad Alghamdi, Waleed K. Al-Hamoudi, Abdulrahman A. Aljumah, Ibrahim H. Altraif, Tarik Asselah, Ziv Ben-Ari, Thomas Berg, Mia J. Biondi, Sarah Blach, Wornei S.M. Braga, Carlos E. Brandão-Mello, Maurizia R. Brunetto, Joaquin Cabezas, Hugo Cheinquer, Pei-Jer Chen, Myeong-Eun Cheon, Wan-Long Chuang, Carla S. Coffin, Nicola Coppola, Antonio Craxi, Javier Crespo, Victor De Ledinghen, Ann-Sofi Duberg, Ohad Etzion, Maria Lucia G Ferraz, Paulo R.A. Ferreira, Xavier Fornis, Graham R. Foster, Giovanni B. Gaeta, Ivane Gamkrelidze, Javier García-Samaniego, Liliana S. Gheorghe, Pierre M. Gholam, Robert G. Gish, Jeffrey Glenn, Julian Hercun, Yao-Chun Hsu, Ching-Chih Hu, Jee-Fu Huang, Naveed Janjua, Jidong Jia, Martin Kåberg, Kelly D.E. Kaita, Habiba Kamal, Jia-Horng Kao, Loreta A. Kondili, Martin Lagging, Pablo Lázaro, Jeffrey V. Lazarus, Mei-Hsuan Lee, Young-Suk Lim, Paul J. Marotta, Maria-Cristina Navas, Marcelo C.M. Naveira, Mauricio Orrego, Carla Osiowy, Calvin Q. Pan, Mário G. Pessoa, Giovanni Raimondo, Alnoor Ramji, Devin M. Razavi-Shearer, Kathryn Razavi-Shearer, Cielo Y. Ríos-Hincapié, Manuel Rodríguez, William M.C. Rosenberg, Dominique M. Roulot, Stephen D. Ryder, Rifaat Safadi, Faisal M. Sanai, Teresa A. Santantonio, Christoph Sarrazin, Daniel Shouval, Frank Tacke, Tammo L. Tergast, Juan Miguel Villalobos-Salcedo, Alexis S. Voeller, Hwai-I Yang, Ming-Lung Yu, Eli Zuckerman	Hepatitis D double reflex testing of all hepatitis B carriers in low HBV and high HBV/high HDV prevalence countries	Journal of Hepatology	79(2)	576-580	2023	○
11)	Imada H, <u>Akita T</u> , <u>Sugiyama A</u> , <u>Tanaka I</u>	Trend of blood donors entering the coronavirus pandemic era and challenges: Age-Period-Cohort analysis using 75.5 million all blood donations data during 2006-2020 in Japan	Transfusion	63(6)	1184-1194	2023	
12)	<u>Shimakami T</u> , Setoyama H, Oza N, Itakura J, Kaneko S, Korenaga M, Toyama T, <u>Tanaka I</u> , Kanto T	Development of performance indicators for hepatitis countermeasures as a tool for the assessment and promotion of liver cancer prevention in Japan	Journal of gastroenterology	58(3)	257-267	2023	○
13)	Ichikawa H, Yasuda E, Kumada T, Takeshima K, Ogawa S, Tsunekawa A, Goto T, Nakaya K, <u>Akita T</u> , <u>Tanaka I</u>	Intra-individual comparison of liver stiffness measurements by magnetic resonance elastography and two-dimensional shear-wave elastography in 888 patients	Ultrasonography	42(1)	65-77	2023	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
14)	Maeshige N, Hayashi H, Terashi H, Fujii M, Iwamoto T, Watanabe Yu, Imaoka S, Matsumoto J, Nishikawa M, Takeda N, Mikawa R, Tsuji Y, Higashita R, Ayabe S, Terabe Y, Furukawa M, <u>Tanaka I</u> , Ohura T, Kawabe N	Effect of early rehabilitation on gait, wound and home discharge in lower extremity chronic wound patients: a Japanese multicenter retrospective study	The International Journal of Lower Extremity Wounds	22(4)	713-721	2023	
15)	Ko K, Phyto Z, Mirzaev U, <u>田中純子</u>	SDGs 目標のウイルス肝炎排除を目指したアジア・アフリカ地域の国際共同疫学研究：HBV に焦点を当てて	アグリバイオ	7(14)	93-101	2023	○
16)	杉山文、 <u>田中純子</u>	感染予防各論 肝炎ウイルス HB ワクチン	臨床透析	39(7)	133-141	2023	○
17)	<u>田中純子</u>	初回供血者および検診受検集団における HB s 抗原陽性率の状況	病原微生物検出情報 (月報)	44(3)	3-4	2023	○
18)	<u>田中純子</u> 、秋田智之、杉山文	SDGs 目標のウイルス肝炎排除を目指したアジア・アフリカ地域の国際共同疫学研究：HBV に焦点を当てて	アグリバイオ	7(4)	56-64	2023	○
19)	<u>Satake M</u> , Yamagishi N, Tanaka A, Goto N, Sakamoto T, Yanagino Y, Furuta RA, Matsubayashi K.	Transfusion-transmitted HBV infection with isolated anti-HBs-positive blood.	Transfusion	63(6)	1250-1254	2023	○
20)	Tanaka A, Yamagishi N, Hasegawa T, Miyakawa K, Goto N, Matsubayashi K, <u>Satake M</u> .	Marked reduction in the incidence of transfusion-transmitted hepatitis B virus infection after the introduction of antibody to hepatitis B core antigen and individual donation nucleic acid amplification screening in Japan.	Transfusion	63(11)	2083-2097	2023	○
21)	Fukano K, Wakae K, Nao N, Saito M, Tsubota A, Toyoshima T, <u>Aizaki H</u> , Iijima H, Matsudaira T, Kimura M, Watashi K, Sugiura W, Muramatsu M.	A versatile method to profile hepatitis B virus DNA integration.	Hepato Comm.	7		2023	○
22)	Oshima M, Stappenbeck F, Ohashi H, Iwamoto M, Fukano K, Kusunoki A, Zheng X, Wang F, Morishita R, <u>Aizaki H</u> , Suzuki R, Muramatsu M, Kuramochi K, Sureau C, Parhami F, Watashi K.	Selective inhibition of hepatitis B virus internalization by oxysterol derivatives.	Biochem Biophys Res Commun.	675	139-145	2023	○
23)	Aoyagi H, Iijima H, Gaber ES, Zaitso T, Matsuda M, Wakae K, Watashi K, Suzuki R, Masaki T, Kahn J, Saito T, El-Kassas M, Shimada N, Kato K, Enomoto M, Hayashi K, Tsubota A, Mimata A, Sakamaki Y, Ichinose S, Muramatsu M, Wake K, <u>Wakita T</u> , <u>Aizaki H</u> .	Hepatocellular organellar abnormalities following elimination of hepatitis C virus.	Liver Int.	43	1677-1690	2023	○
24)	Uchida T, Imamura M, Hayes CN, Suehiro Y, Teraoka Y, Ohya K, Aikata H, Abe-Chayama H, Ishida Y, Tateno C, Hara Y, Hino K, Okamoto T, Matsuura Y, <u>Aizaki H</u> , Wake K, Kohara M, Liang TJ, Oka S, Chayama K.	HBV with precore and basal core promoter mutations exhibits a high replication phenotype and causes ER stress-mediated cell death in humanized liver chimeric mice.	Hepatology.	13		2023	○
25)	Fumitaka Suzuki, <u>Tetsuya Hosaka</u> , Yoshiyuki Suzuki, Hitomi Sezaki, Norio Akuta, Shunichiro Fujiyama, Yusuke Kawamura, Satoshi Saitoh, Yasuji Arase, Mariko Kobayashi, Hiromitsu Kumada.	Clinical outcome after cessation of nucleos(t)ide analog treatment in chronic hepatitis B patients who achieved HBsAg seroclearance	Journal of gastroenterology	59	34-44	2024	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
26)	Tai-Chung Tseng, <u>Tetsuya Hosaka</u> , Chun-Jen Liu, Fumitaka Suzuki, Chieh Chiang, Chun-Ming Hong, Hiromitsu Kumada, Wan-Ting Yang, Tung-Hung Su, Hung-Chih Yang, Chen-Hua Liu, Pei-Jer Chen, Jia-Horng Kao	HBcrAg-based risk score performs better than HBV DNA-based score for HCC prediction in HBeAg-negative grey zone patients	JHEP Reports	6	100956	2023	○
27)	Norio Akuta, Hitomi Sezaki, Shunichiro Fujiyama, Yusuke Kawamura, <u>Tetsuya Hosaka</u> , Mariko Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Yoshiyuki Suzuki, Fumitaka Suzuki, Hiromitsu Kumada.	Simple Predictive Markers and Clinicopathological Features of Primary Liver Cancer following HCV Clearance with Direct-Acting Antivirals	Oncology	101(2):	79-88.	2023	○
28)	Iwamoto H, Suzuki H, Masuda A, Sakaue T, Nakamura T, Tanaka T, Sakai M, Imamura Y, Yano H, Torimura T, <u>Koga H</u> , Yasuda K, Tsurusaki M, Seki T, Kawaguchi T.	A tumor endothelial cell-specific microRNA replacement therapy for hepatocellular carcinoma.	iScience	27(2)	108797	2024	
29)	Sano T, Amano K, Ide T, Isoda H, Honma Y, Morita Y, Yano Y, Nakamura H, Itano S, Miyajima I, Shirachi M, Kuwahara R, Ohno M, Kawaguchi T, Tsutsumi T, Nakano D, Arinaga-Hino T, Kawaguchi M, Eguchi Y, <u>Torimura T</u> , Takahashi H, Harada M, Kawaguchi T; SAKS Study Group.	Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: a multicenter study.	Hepatol Res	(Nov 17)		2023	○
30)	Suzuki H, Iwamoto H, Tanaka T, Sakaue T, Imamura Y, Masuda A, Nakamura T, <u>Koga H</u> , Hoshida Y, Kawaguchi T.	Fibroblast growth factor inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma.	Hepatol Int	(Oct 21)		2023	
31)	Shimose S, Iwamoto H, Niizeki T, Tanaka M, Shirono T, Moriyama E, Noda Y, Nakano M, Suga H, Kuromatsu R, <u>Torimura T</u> , <u>Koga H</u> , Kawaguchi T.	Efficacy of lenvatinib combined with transcatheter intra-arterial therapies for patients with advanced-stage of hepatocellular carcinoma: a propensity score matching.	Int J Mol Sci	24(18)	13715	2023	
32)	Tanaka T, <u>Koga H</u> , Suzuki H, Iwamoto H, Sakaue T, Masuda A, Nakamura T, Akiba J, Yano H, Torimura T, Kawaguchi T.	Anti-PD-L1 antibodies promote cellular proliferation by activating the PD-L1-AXL signal relay in liver cancer cells.	Hepatol Int	(Aug 8)		2023	
33)	Shimose S, Iwamoto H, Shirono T, Tanaka M, Niizeki T, Kajiwaru M, Itano S, Yano Y, Matsugaki S, Moriyama E, Noda Y, Nakano M, Kuromatsu R, <u>Koga H</u> , Kawaguchi T.	The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.	Cancer Med	12(11)	12325-12335	2023	
34)	<u>Koga H</u> , Iwamoto H, Suzuki H, Shimose S, Nakano M, Kawaguchi T.	Clinical practice guidelines and real-life practice in hepatocellular carcinoma: a Japanese perspective.	Clin Mol Hepatol	29(2)	242-251	2023	
35)	Tsumura S, Shimose S, Niizeki T, Kuboyama E, Iwamoto H, Tanaka M, Moriyama E, Shirono T, Takaki K, Noda Y, Nakano M, Inoue M, Tsutsumi K, Kuromatsu R, <u>Koga H</u> , Higuchi K, Kawaguchi T.	Telephone follow-up contributes to improving adherence and treatment duration in patients with hepatocellular carcinoma treated with lenvatinib.	J Gastroenterol Hepatol	38(7)	1140-1147	2023	
36)	Shimose S, Sugimoto R, Hiraoka A, Tanaka M, Iwamoto H, Tanaka Y, Tada F, Ohama H, Niizeki T, Shirono T, Moriyama E, Noda Y, Kamachi N, Nakano M, Kuromatsu R, <u>Koga H</u> , Kawaguchi T.	Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data.	Hepatol Res	53(2)	116-126	2023	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
37)	Minami T, Sato M, <u>Toyoda H</u> , Yasuda S, Yamada T, Nakatsuka T, Enooku K, Nakagawa H, Fujinaga H, Izumiya M, Tanaka Y, Otsuka M, Ohki T, Arai M, Asaoka Y, Tanaka A, Yasuda K, Miura H, Ogata I, Kamoshida T, Inoue K, Nakagomi R, Akamatsu M, Mitsui H, Fujie H, Ogura K, Uchino K, Yoshida H, Hanajiri K, Wada T, Kurai K, Maekawa H, Kondo Y, Obi S, Teratani T, Masaki N, Nagashima K, Ishikawa T, Kato N, Yotsuyanagi H, Moriya K, Kumada T, Fujishiro M, Koike K, Tateishi R	Machine learning for individualized prediction of hepatocellular carcinoma development after the eradication of hepatitis C virus with antivirals.	J Hepatol			in press	○
38)	Iavarone M, Alimenti E, Tada T, Shimose S, Suda G, Yoo C, Solda C, Piscaglia F, Tosetti G, Marra F, Vivaldi C, Conti F, Schirripa M, Iwamoto H, Sho T, Lee SH, Rizzato MD, Tonnini M, Rimini M, Campani C, Masi G, Foschi FG, Bruccoleri M, Kawaguchi T, Kumada T, Hiraoka A, <u>Atsukawa M</u> , Fukunishi S, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Hatanaka T, Kakizaki S, Kawata K, Tada F, Ohama H, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Casadei-Gardini A, Lampertico P	Incidence and predictors of esophagogastric varices bleeding in patients with hepatocellular carcinoma in lenvatinib.	Liver Cancer			in press	
39)	Huang DQ, Hoang JK, Kamal R, Tsai PC, <u>Toyoda H</u> , Yeh ML, Yasuda S, Leong J, Maeda M, Huang CF, Jun DW, Ishigami M, Tanaka Y, Uojima H, Ogawa E, Abe H, Hsu YC, Tseng CH, Alsudaney M, Yang JD, Yoshimaru Y, Suzuki T, Liu JK, Landis C, Dai CY, Huang JF, Chuang WL, Schwartz M, Dan YY, Esquivel C, Bonham A, Yu ML, Nguyen MH	Antiviral therapy utilization and 10-year outcomes in resected HBV- and HCV-related hepatocellular carcinoma.	J Clin Oncol			in press	○
40)	Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Yokohama K, Nishikawa H, Nishimura T, Shimada N, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Aoki T, Tanaka K, Tanaka T, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kudo M, Kumada T	A comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: a multicenter study.	Hepatol Res			in press	
41)	Park JE, Nguyen VH, Tsai PC, <u>Toyoda H</u> , Leong J, Dr. Guy JE, Yeh ML, Huang CF, Yasuda S, Abe H, Hsu YC, Tseng CH, Liu J, Chen YL, Lin PY, Jun DW, Yoshimaru Y, Ogawa E, Ishigami M, Enomoto M, Tamori A, Uojima H, Wang XZ, Xu Q, Takahashi H, Eguchi Y, Inoue K, Huang DQ, Zhao WJ, Chuang WL, Dai CY, Huang JF, Barnett S, Maeda M, Cheung R, Landis C, Tanaka Y, Roberts LR, Schwartz ME, Kumada T, Yu ML, Nguyen MH	Racial and ethnic disparities in untreated patients with hepatitis C virus-related hepatocellular carcinoma but not in those with sustained virologic response.	Aliment Pharmacol Ther			in press	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
42)	<u>Toyoda H</u> , Kanneganti M, Melendez-Torres J, Parikh ND, Jalal PK, Pinero F, Mendizabal M, Ridruejo E, Cheinquer H, Casadei-Gardini A, Weinmann A, Peck-Radosavljevic M, Dufour JF, Radu P, Shiha G, Soliman R, Sarin SK, Kumar M, Wang JH, Tangkijvanich P, Sukeepaisarnjaroen W, <u>Atsukawa M</u> , Uojima H, Nozaki A, Nakamuta M, Takaguchi K, Hiraoka A, Abe H, Matsuura K, Watanabe T, Shimada N, Tsuji K, Ishikawa T, Mikami S, Itobayashi E, Singal AG, Johnson PJ	Regional differences in clinical presentation and prognosis of patients with post-sustained virologic response (SVR) hepatocellular carcinoma.	Clin Gastroenterol Hepatol	22	72-80	2024	○
43)	Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Shibata H, Aoki T, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Kaibori M, Hiasa Y, Kudo M	Does first-line treatment have prognostic impact for unresectable HCC? – atezolizumab plus bevacizumab vs. lenvatinib.	Cancer Med	12	325-334	2023	
44)	Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Shimada N, Kawata K, Kosaka H, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano Y, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Kaibori K, Iijima H, Hiasa Y, Kumada T	Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non-viral infection: a Japanese multicenter observational study.	Cancer Med	12	5293-5303	2023	
45)	Hatanaka T, Kakizaki S, Hiraoka A, Kariyama K, Tsuji K, Ishikawa T, <u>Toyoda H</u> , Yasuda S, Naganuma A, Tada T, Takaguchi K, Tsutsui A, Itobayashi E, Shimada N, Shibata H, Tanaka T, Nagano T, Imai M, Nakamura S, Nouse K, Kosaka H, Kaibori M, Kumada T	The prognosis of elderly patients with hepatocellular carcinoma: a multi-center 19-year experience in Japan.	Cancer Med	12	345-357	2023	
46)	Ito T, Nguyen VH, Tanaka T, Park H, Yeh ML, Kawanaka M, Arai T, <u>Atsukawa M</u> , Yoon E, Tsai PC, <u>Toyoda H</u> , Huang JF, Henry L, Jun DW, Yu ML, Ishigami M, Nguyen MH, Cheung RC	Poor diagnostic efficacy of noninvasive tests for advanced fibrosis in obese or younger than 60 diabetic NAFLD patients.	Clin Gastroenterol Hepatol	21	1013-1022	2023	
47)	Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Shimada N, Kawata K, Kosaka H, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kumada T.	Development and validation of a modified albumin-bilirubin grade and α -fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab.	Hepatol Int	17	86-96	2023	
48)	Lee CM, Yoon EL, Nakajima A, Yoneda M, <u>Toyoda H</u> , Yasuda S, Lee J, Kim M, Kang BK, Nguyen MH, Jun DW, Sumida Y	A reappraisal of the diagnostic performance of B-mode ultrasonography for mild liver steatosis.	Am J Gastroenterol	118	840-847	2023	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
49)	Hatanaka T, Naganuma A, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Shimada N, Kawata K, Kosaka H, Kakizaki S, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa H, Kumada T	The hepatocellular carcinoma modified Gustave Roussy Immune Score (HCC-GRIm-Score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: a multicenter retrospective analysis.	Cancer Med	12	4259-4269	2023	
50)	Hayama K, <u>Atsukawa M</u> , Tsubota A, Kondo C, Iwasa M, Hasegawa H, Takaguchi K, Tsutsui A, Uojima H, Hidaka H, Okubo H, Suzuki T, Matsuura K, Tada T, Kawabe N, Tani J, Morishita A, Ishikawa T, Arase Y, Furuichi Y, Kato K, Kawata K, Chuma M, Nozaki A, Hiraoka A, Watanabe T, Kagawa T, <u>Toyoda H</u> , Taniai N, Yoshida H, Tanaka Y, Iwakiri K	Clinical outcomes of antithrombin III-based therapy for patients with portal vein thrombosis: a retrospective, multicenter study.	Hepatol Res	53	51-60	2023	
51)	Tada T, Kumada T, Hiraoka A, Kariyama K, Tani J, Hirooka M, Takaguchi K, <u>Atsukawa M</u> , Fukunishi S, Itobayashi E, Tsuji K, Tajiri K, Ochi H, Ishikawa T, Yasuda S, Ogawa C, <u>Toyoda H</u> , Hatanaka T, Nishimura T, Kakizaki S, Kawata K, Shimada N, Tada F, Nouse K, Tsutsui A, Ohama H, Morishita A, Nagano T, Itokawa N, Okubo T, Arai T, Kosaka H, Imai M, Naganuma A, Nakamura S, Koizumi Y, Matono T, Kaibori M, Iijima H, Hiasa Y	Nutritional status is associated with prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.	Oncology	101	270-282	2023	
52)	<u>Atsukawa M</u> , Tsubota A, Kondo C, Shioda-Koyano K, Ishikawa T, <u>Toyoda H</u> , Takaguchi K, Watanabe T, Matsuura K, Ogawa C, Hiraoka A, Okubo H, Tateyama M, Uojima H, Nozaki A, Chuma M, Kato K, Mikami S, Tani J, Morishita A, Kawata K, Tada T, Furuichi Y, Okubo T, Kawano T, Arai T, Kawabe N, Kawamura N, <u>Ikegami T</u> , Nakamuta M, Iwasa M, Tanaka Y, Hatano M, Iwakiri K	Risk factors for portopulmonary hypertension in patients with cirrhosis: a prospective multicenter study.	Hepatol Int	17	139-149	2023	
53)	Tada T, Kumada T, Hiraoka A, Kariyama K, Tani J, Hirooka M, Takaguchi K, <u>Atsukawa M</u> , Fukunishi S, Itobayashi E, Tsuji K, Tajiri K, Ochi H, Ishikawa T, Yasuda S, Ogawa K, <u>Toyoda H</u> , Hatanaka T, Nishimura T, Kakizaki S, Kawata K, Shimada N, Tada F, Nouse K, Tsutsui A, Ohama A, Morishita A, Nagano T, Itokawa N, Okubo T, Arai T, Kosaka H, Imai M, Naganuma A, Nakamura S, Koizumi Y, Kaibori M, Iijima H, Hiasa Y	New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a validation study.	Cancer Med	12	6980-6993	2023	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
54)	Casadei-Gardini A, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada K, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Solda C, Piscaglia F, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Scartozzi M, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Persano M, Della Corte A, Ratti F, De Cobelli F, Aldrighetti L, Cascinu S, Cucchetti A	Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real life worldwide population.	Eur J Cancer	180	9-20	2023	
55)	Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Noritomo S, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y	Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab.	Cancer Med	12	7772-7783	2023	
56)	Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Yoo C, Lonardi S, Stefanini B, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Montes M, Vivaldi C, Solda C, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Della Corte A, Ratti F, De Cobelli F, Aldrighetti L, Scartozzi M, Cascinu S, Casadei-Gardini A	Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab.	Oncology	101	283-291	2023	
57)	<u>Toyoda H</u> , Kariyama K, Hiraoka A	Letter: rising incidence and poor survival in patients with nonviral HCC – better HCC surveillance and treatment for alcohol-associated and non-alcohol fatty liver diseases are needed. authors' reply.	Aliment Pharmacol Ther	57	363-364	2023	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
58)	Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Kawaguchi T, Montes M, Vivaldi C, Solda C, Piscaglia F, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Scartozzi M, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Cammarota A, Burgio V, Cascinu S, Casadei-Gardini A	Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study.	J Cancer Res Clin Oncol	149	5591-5602	2023	
59)	Seko Y, Takahashi H, <u>Toyoda H</u> , Hayashi H, Yamaguchi K, Iwaki M, Yoneda M, Arai T, Shima T, Fujii H, Morishita A, Kawata K, Tomita K, Kawanaka M, Yoshida Y, <u>Ikegami T</u> , Notsumata K, Oeda S, Kamada Y, Sumida Y, Fukushima H, Miyoshi E, Aishima S, Okanoue T, Nakajima A, Itoh Y, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)	Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis-related fibrosis: multicenter study.	Hepatol Res	53	312-321	2023	
60)	中川俊一郎, 岩本淳一, 高木亮輔, 森山由貴, 柿崎文郎, 玉虫惇, 門馬匡邦, 小西直樹, 屋良昭一郎, 平山剛, 池上正.	免疫チェックポイント阻害剤投与後に発症した小腸炎の一例.	Progress of Digestive Endoscopy.	104(1)	93-4	2023	
61)	Fujii H, Fujii M, Iwaki M, Hayashi H, <u>Toyoda H</u> , Oeda S, Hyogo H, Kawanaka M, Morishita M, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Kawada N, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)	A multicenter, retrospective, cohort study shows platelet counts predict HCC development in patients with NAFLD.	Hepatol Res	53	391-400	2023	
62)	Watanabe M, <u>Toyoda H</u> , Kawabata T	Rapid quantification assay of hepatitis B virus DNA in human serum and plasma by fully automated genetic analyzer μ TAS Wako g1.	PLoS ONE	18	e0278143	2023	
63)	Ishiba H, Sumida Y, Kamada Y, Fujii H, Iwaki M, Hayashi H, <u>Toyoda H</u> , Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Takahashi H, Ueda S, Aishima S, Nakajima A, Okanoue T, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)	Noninvasive tests predict liver-related events and mortality in patients with non-alcoholic fatty liver disease: sub-analysis of the CLIONE-Asia study.	J Gastroenterol Hepatol	38	896-904	2023	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
64)	Oeda S, Seko Y, Hayashi H, Arai T, Iwaki M, Yoneda M, Shima T, Notsumata K, <u>Ikegami T</u> , Fujii H, <u>Toyoda H</u> , Miura K, Morishita A, Kawata K, Tomita K, Kawanaka M, Isoda H, Yamaguchi K, Fukushima H, Kamada Y, Sumida Y, Aishima S, Itoh Y, Okanou T, Nakajima A, Takahashi H, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)	Validation of the utility of Agile scores to identify advanced fibrosis and cirrhosis in Japanese patients with nonalcoholic fatty liver disease.	Hepatol Res	53	489-496	2023	
65)	Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Matono T, Shibata H, Aoki T, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, Kudo M, Kumada T	Comparison between atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma in patients with Child-Pugh class B in real-world clinical settings.	Oncology	101	542-552	2023	
66)	Rimini M, Persano M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Presa J, Salani F, Lonardi S, Piscaglia F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Schirripa M, Montes M, Vivaldi C, Solda C, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Scartozzi M, Cascinu S, Casadei-Gardini A	Survival outcomes from atezolizumab plus bevacizumab versus lenvatinib versus sorafenib in Child Pugh B unresectable hepatocellular carcinoma patients.	J Cancer Res Clin Oncol	149	7565-7577	2023	
67)	Hiraoka A, Kumada T, Tada T, <u>Toyoda H</u> , Kariyama K, Hatanaka T, Kakizaki S, Naganuma A, Itobayashi E, Tsuji K, Ishikawa T, Ohama H, Tada F, Nouse K	Attempt to establish prognostic predictive system for hepatocellular carcinoma using artificial intelligence for assistance with selection of treatment modality.	Liver Cancer	25	565-575	2023	
68)	<u>Toyoda H</u>	Low surveillance receipt in cirrhotic patients with cured HCV: where are the barriers?	Liver Int	43	962-963	2023	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
69)	Rimini M, Persano M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Yoo C, Lonardi S, Piscaglia F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Solda C, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Rimassa L, Scartozzi M, Cascinu S, Casadei-Gardini A	Real-world data for atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: how does adherence to the IMbrave150 trial inclusion criteria impact prognosis?	Target Oncol	18	221-233	2023	
70)	Yamauchi R, Ito T, Yoshio S, Yamamoto T, Mizuno K, Ishigami M, Kawashima H, Yasuda S, Shimose S, Iwaomto H, Yamazoe T, Mori T, Kakazu E, Kawaguchi T, <u>Toyoda H</u> , Kanto T.	Serum osteopontin as a predictive biomarker for the response to atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma.	J Gastroenterol	58	565-574	2023	
71)	Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Shimada N, Kawata K, Kosaka H, Naganuma A, Yata Y, Tanaka T, Ohama H, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kumada T, the Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)	Association of PPI and antibiotics with the clinical outcomes of HCC patients receiving atezolizumab and bevacizumab: a multicenter analysis.	Hepatol Res	53	737-748	2023	
72)	Huang DQ, Tran A, Yeh ML, Yasuda S, Tsai PC, Huang CF, Dai CY, Ogawa E, Ishigami M, Ito T, Kozuka R, Enomoto M, Suzuki T, Yoshimaru Y, Preda CM, Marin RI, Sandra I, Tran S, Quek SXZ, Khine HHTW, Itokawa N, <u>Atsukawa M</u> , Uojima H, Watanabe T, Takahashi H, Inoue K, Maeda M, Hoang JK, Trinh L, Barnett S, Cheung R, Lim SG, Trinh HN, Chuang WL, Tanaka Y, <u>Toyoda H</u> , Yu ML, Nguyen MH	Antiviral therapy substantially reduces hepatocellular carcinoma risk in chronic hepatitis B patients in the indeterminate phase.	Hepatology	78	1558-1568	2023	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
73)	Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Ohama H, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, on behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)	Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.	Hepatol Res	53	1031-1042	2023	
74)	Takahashi H, Kawanaka M, Fujii H, Iwaki M, Hayashi H, <u>Toyoda H</u> , Oeda S, Hyogo H, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Kamada Y, Ueda S, Nakajima A, Sumida Y, Okanoue T	Association of serum albumin levels and long-term prognosis in patients with biopsy-confirmed nonalcoholic fatty liver disease.	Nutrients	15	2014	2023	
75)	Yamamoto T, Mizuno K, Ito T, Yokoyama S, Yamamoto K, Imai N, Ishizu Y, Honda T, Ishikawa T, Kanamori A, Yasuda S, <u>Toyoda H</u> , Yokota K, Hase T, Nishio N, Maeda O, Ishii M, Sone M, Ando Y, Akiyama M, Ishigami M, Kawashima H	Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis.	Invest New Drugs	41	512-521	2023	
76)	Imajo K, Saigusa Y, Kobayashi T, Nagai K, Nishida S, Kawamura N, Doi H, Iwaki M, Nogami A, Honda Y, Kessoku T, Ogawa Y, Kirikoshi H, Yasuda S, <u>Toyoda H</u> , Hayashi H, Kokubu S, Utsunomiya D, Takahashi H, Aishima S, Kim BK, Tamaki N, Saito S, Yoneda M, Loomba R, Nakajima A	M-PAST score is better than MAST score for the diagnosis of active fibrotic NASH.	Hepatol Res	53	844-856	2023	
77)	<u>Toyoda H</u> , <u>Kikuchi K</u>	Management of dialysis patients with HCV in the era of direct-acting antiviral therapy.	Ther Apher Dial	27(5)	831-838	2023	○
78)	Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Matono T, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y	Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.	J Gastroenterol Hepatol	38	1389-1397	2023	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
79)	Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Ohama H, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Yokohama K, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y	Lenvatinib as second-line treatment after atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma –clinical results show importance of hepatic reserve function.	Oncology	101	624-633	2023	
80)	Hatanaka T, Kakizaki S, Hiraoka A, <u>Toyoda H</u> , Kumada T	Reply to: “Developing real-world prognostic models for patients with advanced hepatocellular carcinoma: CRAFTY, mALF and beyond”.	Hepatol Int	17	1320-1321	2023	
81)	Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Niizeki T, Montes M, Vivaldi C, Solda C, Stefanini B, Hiraoka A, Sho T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Campani C, Amadeo E, Rossari F, Burgio V, Cascinu S, Scartozzi M, Casadei-Gardini A	Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients.	Eur J Cancer	189	112933	2023	
82)	Wong YJ, Tran S, Huang CF, Hsu YC, Preda C, <u>Toyoda H</u> , Liu J, Jun DW, Landis C, Huang DQ, Gila A, Negoita L, Yasuda S, Tseng CH, Tsai PC, Uojima H, Nozaki A, Chuma M, <u>Atsukawa M</u> , Ishigami M, Itokawa N, Iio E, Lam CP, Watanabe T, Asai A, Yokohama K, Abe H, Enomoto M, Kawada N, Tamori A, Lee DH, Jun MJ, Do S, Vo DKH, Liu L, Li J, Ji F, Wang W, Li Y, Wang X, Guo F, Xu Q, Jing L, Ye Q, Pan H, Zhang J, Wen X, Wang Q, Ren H, Cai D, Shang J, Liu J, Lu C, Zang W, Li J, Niu J, Zhang M, Wu C, Huang R, Maeda M, Nakanishi A, Yeh ML, Chuang WL, Huang JF, Dai C, Ishikawa T, Takaguchi K, Senoh T, Trinh HN, Takahashi H, Eguchi Y, Quek SXZ, Haga H, Ogawa E, Wong G, Buti M, Fukunishi S, Ueno Y, Yuen MF, Tanaka Y, Lim SG, Cheung R, Yu ML, Nguyen MH	Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study.	Hepatol Int	17	1150-1161	2023	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
83)	Hamill V, Wong S, Benselin J, Krajden M, Hayes PC, Mutimer D, Yu A, Dillon JF, Gelson W, Velasquez Garcia HA, Yeung A, Johnson P, Barclay ST, Alvarez M, <u>Toyoda H</u> , Agarwal K, Fraser A, Bartlett S, Aldersley M, Bathgate A, Binka M, Richardson P, Morling JR, Ryder SD, MacDonald D, Hutchinson S, Barnes E, Guha IN, Irving WL, Janjua NZ, Innes H	Mortality rates among patients achieving a hepatitis C cure in the interferon-free treatment era: data from three population cohorts.	Br Med J	382	e074001	2023	○
84)	Tada F, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Yokohama K, Nishikawa H, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, Kumada T	Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal-gastric varices.	J Gastroenterol	58	1134-1143	2023	
85)	Kuroda H, Oguri T, Kamiyama N, <u>Toyoda H</u> , Yasuda S, Imao K, Suzuki Y, Sugimoto K, <u>Akita T</u> , <u>Tanaka J</u> , Yasui Y, Kurosaki M, Izumi N, Nakajima A, Fujiwara Y, Abe T, Kakisaka K, Matsumoto T, Kumada T	Multivariable quantitative US parameters for assessing hepatic steatosis.	Radiology	309	e230341	2023	
86)	<u>Toyoda H</u> , Fujii H, Iwaki M, Hayashi H, Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Yamamura S, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Kawada N, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T, the Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)	Validation of noninvasive markers for HCC risk stratification in 1,389 patients with biopsy-proven NAFLD.	Gastro Hep Adv	2	1093-1102	2023	
87)	Nouse K, Shiota S, Fujita R, Wakuta A, Kariyama K, Hiraoka A, <u>Atsukawa M</u> , Tani J, Tada T, Nakamura S, Tajiri K, Kaibori M, Hirooka M, Itobayashi E, Kakizaki S, Naganuma A, Ishikawa T, Hatanaka T, Fukunishi S, Tsuji K, Kawata K, Takaguchi K, Tsutsui A, Ogawa C, Ochi H, Yata Y, Kuroda H, Iijima H, Matono T, Shimada N, Yasuda S, <u>Toyoda H</u> , Kumada T	Effect of butyrate-producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab.	Cancer Med	12	17849-17855	2023	
88)	Ito T, Morooka H, Takahashi H, Fujii H, Iwaki M, Hayashi H, <u>Toyoda H</u> , Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Ishigami M, Kamada Y, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T for the Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)	Identification of clinical phenotypes associated with poor prognosis in patients with NAFLD via unsupervised machine learning.	J Gastroenterol Hepatol	38	1832-1839	2023	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
89)	Nouso K, Shiota S, Fujita R, Wakuta A, Kariyama K, Hiraoka A, <u>Atsukawa M</u> , Tani J, Tada T, Matsuo Y, Nakamura S, Tajiri K, Kaibori M, Hirooka M, Itobayashi E, Kakizaki S, Naganuma A, Ishikawa T, Hatanaka T, Fukunishi S, Tsuji K, Kawata K, Takaguchi K, Tsutsui A, Ogawa C, Ochi H, Yasuda S, <u>Toyoda H</u> , Kumada T	Characteristics of cabozantinib treatment in advanced hepatocellular carcinoma.	Liver Cancer Int	4	101-108	2023	
90)	Park H, Yoon EL, Ito T, Jo AJ, Kim M, Lee J, Kim HL, Arai T, <u>Atsukawa M</u> , Kawanaka M, <u>Toyoda H</u> , Ishigami M, Yu ML, Jun DW, Nguyen MH	Diagnostic performance of the fibrosis-4 index and nonalcoholic fatty liver disease fibrosis score in lean adults with nonalcoholic fatty liver disease.	JAMA Netw Open	6	e2329568	2023	
91)	Tanaka K, Tsuji K, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Ishikawa T, Tajiri K, Ochi H, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Yokohama K, Nishikawa H, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, Kumada T	Usefulness of tumor marker score for prediction of prognosis in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study.	Cancers	15	4348	2023	
92)	Uojima H, Nakabayashi K, Yamasaki K, Sugiyama M, Ishii N, Shirabe K, Kyotou T, Ueda K, Takahama Y, Tamaki N, Kurosaki M, Hidaka H, Kusano C, Amano K, Kawaguchi T, Taketomi A, Joshita S, Umemura T, Murakawa M, Asahina Y, Suzuki T, Matsuura K, Nishimura T, Iijima H, Sakamoto K, Ito K, <u>Nishina S</u> , Hino K, <u>Toyoda H</u> , Yatsushashi H, Kage M, Mizokami M	New chemiluminescent enzyme immunoassay for quantitative measurement of Mac-2 binding protein glycosylation isomer in chronic liver disease.	J Gastroenterol	58	1252-1260	2023	
93)	Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Yokohama K, Nishikawa H, Nishimura T, Shimada N, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Tanaka K, Tanaka T, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Kudo M, Kumada T	Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: a mixed-effects regression model approach.	Cancer Med	12	21680-21693	2023	
94)	Yoshida Y, Ito A, Eto H, Suzuki A, Abe T, Kakisaka K, Oikawa T, Kuroda H, <u>Miyasaka A</u> , Matsumoto T, Takahashi M, Okamoto H	Seroprevalence and incidence of hepatitis E virus infection in the general population of Iwate prefecture, Japan: A retrospective cohort study	Hepatol Res.	54	24-31	2024	
95)	<u>Miyasaka A</u> , Yoshida Y, Suzuki A, Endo K, Kakisaka K, Oikawa T, Abe T, Obara W, Matsumoto T	Current elimination status of hepatitis C virus-infected maintenance hemodialysis patients in Iwate Prefecture, Japan	Ther Apher Dial	27	848-854	2023	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
96)	Kakisaka K, Kuroda H, Abe T, Nakaya I, Watanabe T, Yusa K, Sato H, Suzuki A, Kooka Y, Endo K, Yoshida Y, Oikawa T, <u>Miyasaka A</u> , Matumoto T	Coincidental items in the definition of metabolic dysfunction-associated fatty liver are useful in identifying patients having significant fibrosis with fatty liver.	Hepatol Res.	53	857-865	2023	
97)	Kishimoto K, Kakisaka K, Abe T, Ito A, Yusa K, Suzuki A, Endo K, Yoshida Y, Oikawa T, <u>Miyasaka A</u> , Sato A, Nishiya M, Yanagawa N, Kuroda H, Matsumoto T	A Case of Autoimmune Hepatitis Complicated by Undiagnosed Factor VII Deficiency: A Pitfall of Coagulopathy	Intern Med.		doi: 10.2169/internalmedicine.2854-23.	2023	
98)	Yamamoto M, Terashima T, Yamashita T, Seki A, Nakagawa H, Nio K, <u>Shimakami T</u> , Takatori H, Arai K, Mizukoshi E, Honda M, Takeuchi S, Yamashita T.	Successful second-line treatment with cabozantinib for hepatocellular carcinoma harboring cytoplasmic mesenchymal-epithelial transition factor amplification.	Hepatol Res.	54(3)	315-319	2024	
99)	Hayashi T, Terashima T, Nishitani M, Orita N, Miyazawa M, Seki A, Nakagawa H, Nio K, Iida N, Yamada S, Takatori H, <u>Shimakami T</u> , Yamashita T.	Gastroduodenitis Associated with Active Ulcerative Colitis Treated with Infliximab~Different Clinical Course in the Colon and Gastroduodenal Lesions~.	Intern Med.			in press	
100)	Miyazawa M, Yanagi M, Chiba T, Kido H, Matsuo T, Nishitani M, Orita N, Takata N, Hayashi T, Seki A, Nakagawa H, Nio K, Terashima T, Iida N, Yamada S, Takatori H, <u>Shimakami T</u> , Arai K, Yamashita T, Mizukoshi E, Honda M, Yamashita T.	Post-allogeneic Hematopoietic Stem Cell Transplantation Portal Hypertension Not Associated with Liver Cirrhosis, Veno-occlusive Disease, or Graft-versus-host Disease: A Case Report.	Intern Med.			in press	
101)	Hayashi T, Hayashi K, Terashima T, Nishitani M, Orita N, Miyazawa M, Seki A, Nakagawa H, Nio K, Iida N, Yamada S, Takatori H, <u>Shimakami T</u> , Yamashita T.	Photodynamic therapy with talaporfin sodium for endoscopically unresectable gastric cancer using a novel simultaneous light-emitting method.	DEN Open.	4(1)	e334	2024	
102)	Shirasaki T, Murai K, Ishida A, Kuroki K, Kawaguchi K, Wang Y, Yamanaka S, Yasukawa R, Kawasaki N, Li YY, <u>Shimakami T</u> , Sumiyadorj A, Nio K, Sugimoto S, Orita N, Takayama H, Okada H, Thi Bich PD, Iwabuchi S, Hashimoto S, Ide M, Tabata N, Ito S, Matsushima K, Yanagawa H, Yamashita T, Kaneko S, Honda M.	Functional involvement of endothelial lipase in hepatitis B virus infection.	Hepatol Commun.	7(9)	e0206	2023	
103)	Orita N, Kawaguchi K, Honda M, Shimode T, Hayakawa N, Terashima T, Komura T, Nishikawa M, Horii R, Nio K, <u>Shimakami T</u> , Takatori H, Arai K, Sakai Y, Yamashita T, Mizukoshi E, Kaneko S, Kagaya T, Yamashita T.	Aldo-keto reductase family 1 member B10 is regulated by nucleos(t)ide analogues for chronic hepatitis B.	Biochem Biophys Res Commun.	674	133-139	2023	
104)	Doan PTB, Nio K, <u>Shimakami T</u> , Kuroki K, Li YY, Sugimoto S, Takayama H, Okada H, Kaneko S, Honda M, Yamashita T.	Super-Resolution Microscopy Analysis of Hepatitis B Viral cccDNA and Host Factors.	Viruses.	15(5)	1178	2023	
105)	Suda T, Takatori H, Hayashi T, Kaji K, Nio K, Terashima T, <u>Shimakami T</u> , Arai K, Yamashita T, Mizukoshi E, Honda M, Okumura K, Kozaka K, Yamashita T.	Plasma Antithrombin III Levels Can Be a Prognostic Factor in Liver Cirrhosis Patients with Portal Vein Thrombosis.	Int J Mol Sci.	24(9)	7732	2023	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
106)	出島彰宏, 島上哲朗, 寺島健志, 堀井里和, 山田真也, 丹尾幸樹, 鷹取元, 荒井邦明, 山下竜也, 本多政夫, 金子周一, 山下太郎.	オンラインツールを用いた指定医療機関拡充による C 型慢性肝疾患患者への治療導入の促進	肝臓	65(3)	139-142	2024	
107)	<u>Toyoda H, Kikuchi K</u>	Authors response to Management of dialysis patients with hepatitis C virus in the era of direct-acting antiviral therapy.	Ther Apher Dial.	28(1)	160-161	2024	○
108)	<u>Kikuchi K</u> , et al.	Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with COVID-19 in clinical practice during the Omicron (BA.1 and BA.2) pandemic	Ther Apher Dial.	27(6)	1064-1069	2023	
109)	Hashiba T, <u>Kikuchi K</u> , et al	Infection prevention measures for patients on hemodialysis during COVID-19 pandemic in Japan: a nationwide questionnaire follow-up survey in 2022	Renal Replacement Therapy			2023	
110)	Toda M, <u>Kikuchi K</u> , et al	Cellular and Humoral Immune Responses after Breakthrough Infection in Patients Undergoing Hemodialysis	Vaccines			2023	
111)	Murakami M, <u>Kikuchi K</u> , et al	Association of four types of vascular access including arterial superficialization with mortality in maintenance hemodialysis patients: a nationwide cohort study in Japan	Am J Nephrol	54(3-4)	83-94	2023	
112)	Katagiri D, <u>Kikuchi K</u>	The Impact and Treatment of COVID-19 in Hemodialysis Patients	J Clin Med			2023	
113)	Yoshifuji A, <u>Kikuchi K</u> , et al	T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis	Vaccines			2023	
114)	Miyazaki T, Ueda H, <u>Ikegami T</u> , Honda A	Upregulation of taurine biosynthesis and bile acid conjugation with taurine through FXR in a mouse model with human-like bile acid composition	Metabolites	13(7)	824	2023	
115)	Sato M, Akamatsu M, Shima T, <u>Ikegami T</u> , Yanase M, Mikami S, Imamura J, Nakatsuka T, Tateishi R, Yamauchi N, Ushiku T, Okanoue T, Fujishiro M, Hida E, Koike K.	Impact of a Novel Digital Therapeutics System on Nonalcoholic Steatohepatitis: The NASH App Clinical Trial	Am J Gastroenterol	118(8)	1365-1372	2023	
116)	柿崎文郎, 岩本淳一, 門馬匡邦, 玉虫惇, 上田元, 小西直樹, 屋良昭一郎, 宮崎照雄, 池上正, 本多彰	西欧食による腸内細菌叢と胆汁酸代謝への影響	消化と吸収	45(2)	119-122	2023	
117)	Imai K, Takai K, Unome S, Miwa T, Hanai T, Suetsugu A, <u>Shimizu M</u> .	FIB 4 index and NAFLD fibrosis score are useful indicators for screening high risk groups of non viral hepatocellular carcinoma.	Mol Clin Oncol	19	80	2023	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
118)	Hanai T, Kawaratani H, Nagano J, Suii H, Sakamaki A, Arase Y, Nakanishi H, Kogiso T, Okubo T, Miwa T, Shimizu S, Hige S, <u>Atsukawa M</u> , <u>Shimizu M</u> , Kurosaki M, Terai S, Kagawa T, Tokushige K, Yoshiji H.	Cell-free and concentrated ascites reinfusion therapy vs. large-volume paracentesis for the treatment of cirrhotic patients with refractory ascites: A multicenter prospective observational study.	Hepatol Res	53	238-246	2023	○
119)	Hanai T, Nishimura K, Miwa T, Maeda T, Imai K, Suetsugu A, Takai K, <u>Shimizu M</u> .	Prevalence, association, and prognostic significance of polypharmacy and sarcopenia in patients with liver cirrhosis.	JGH Open	7	208-214	2023	○
120)	Miwa T, Hanai T, Nishimura K, Tajirika S, Nakahata Y, Imai K, Suetsugu A, Takai K, Yamamoto M, <u>Shimizu M</u> .	Association between body composition and the risk of portopulmonary hypertension assessed by computed tomography in patients with liver cirrhosis.	J Clin Med	12	3351	2023	○

令和 4(2022)年度 研究成果の刊行に関する一覧表 【書籍】

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ	関連
1) 田中純子、秋田智之、杉山文	SDGs 目標のウイルス肝炎排除を目指したアジア・アフリカ地域の国際共同疫学研究：HBV に焦点を当てて	月刊「アグリバイオ」編集委員会	アグリバイオ	北隆館	東京	2023		○
2) 田中純子	わが国における HCV 感染症の疫学-最近の疫学と HCV elimination の見通し		臨床消化器内科	日本メディカルセンター	東京	2022		○
3) 田中純子、小山富子	肝炎ウイルス検診におけるアキュラシード HCV[II] の有用性評価		医学と薬学	自然科学出版	東京	2022		○
4) 田中純子、Ouoba Serge、E Bunthen	SDGs 目標のウイルス肝炎排除を目指したアジア・アフリカ地域の国際共同疫学研究：HBV に焦点を当てて	月刊「アグリバイオ」編集委員会	アグリバイオ	北隆館	東京	2022		○
5) 相崎英樹	日本の感染症の発生状況	菅又昌実	日本の感染症—明らかにされたことと残された課題—	南山堂	東京	2022	13-34	○
6) 相崎英樹、青柳東代、杉山真也、村松正道、溝上雅史、脇田隆字	HCV 排除後の肝発癌における課題 HCV 駆除後発癌の基礎的考察—形態とゲノムからの考察—		臨床消化器内科	日本メディカルセンター	東京	2022	914-919	
7) 保坂哲也	HBV 増殖制御下の B 型肝炎における肝癌発生の現状とリスク因子	小池和彦	臨床消化器内科 8 月号	日本メディカルセンター	東京	2022	921	○
8) 保坂哲也	高感度 HB コア関連抗原測定 of 臨床的意義	消化器・肝臓内科編集委員会	消化器・肝臓内科 12 月号	科学評論社	東京	2022	670	○
9) 保坂哲也	B 型肝炎核酸アナログ治療下の発癌リスク評価	「肝胆膵」編集委員会	肝胆膵	アークメディア	東京	2022	79	○

発表者氏名		論文タイトル名	発表誌名	巻号	ページ	出版年	関連
1)	Imajo K, <u>Toyoda H</u> , Yasuda S, Suzuki Y, Sugimoto K, Kuroda H, <u>Akita T</u> , <u>Tanaka J</u> , Yasui Y, Tamaki N, Kurosaki M, Izumi N, Nakajima A, Kumada T	Utility of ultrasound-guided attenuation parameter for grading steatosis with reference to MRI-PDFF in a large cohort	Clinical gastroenterology and hepatology	in press	in press	2023	
2)	Nobuhara H, Matsugu Y, <u>Tanaka J</u> , <u>Akita T</u> , Ito K	The preventive effects of perioperative oral care on surgical site infections after pancreatic cancer surgery: a retrospective study	Support Care Cancer	30(4)	3337-3344	2022	
3)	Matsugu Y, Ito K, Oshita A, Nobuhara H, <u>Tanaka J</u> , <u>Akita T</u> , Itamoto T	Postoperative oral energy and protein intakes for an enhanced recovery after surgery program incorporating early enteral nutrition for pancreaticoduodenectomy: A retrospective study	Nutrition in Clinical Practice	37(3)	654-665	2022	
4)	Hayes NC, Imamura M, <u>Tanaka J</u> , Chayama K	Road to elimination of HCV: Clinical challenges in HCV management	Liver International	42(9)	1935-1944	2022	○
5)	Blach S, Terrault NA, Tacke F, et al, (<u>Tanaka J</u> 含む 259 人中 6 番目)	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study	The LANCET Gastroenterology and Hepatology	7(5)	396-415	2022	○
6)	<u>Toyoda H</u> , Yasuda S, Shiota S, Kumada T, <u>Tanaka J</u>	Adherence to regular surveillance visits for hepatocellular carcinoma in patients with chronic hepatitis C virus infection who achieved sustained virologic response	European Journal of Gastroenterology and Hepatology	34(6)	693-697	2022	○
7)	Kitagawa H, Kaiki Y, <u>Sugiyama A</u> , Ngashima S, Kurisu A, Nomura T, Omori K, <u>Akita T</u> , Shigemoto N, <u>Tanaka J</u> , Ohge H	Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan	Journal of infection and chemotherapy	28(4)	576-581	2022	
8)	<u>Toyoda H</u> , Yasuda S, Shiota S, Sone Y, Maeda A, Kaneoka Y, Kumada T, <u>Tanaka J</u>	Identification of the suitable candidates for EOB-MRI with the high risk of the presence of non-hypervascular hypointense nodules in patients with HCV infection	European Radiology	32(7)	5016-5023	2022	○
9)	Manry J, Bastard P, Gervais A, et al, (<u>Tanaka J</u> 含む 180 人中 38 番目)	The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies	Proceedings of the National Academy of Sciences of the United States of America	119(21)	e2200413119	2022	
10)	El-Ekiaby M, <u>Tanaka J</u> , van Drimmelen H, Allain JP, Lelie N	Infectivity of hepatitis B virus (HBV) surface antigen (HBsAg) positive plasma with undetectable HBV-DNA: Can HBsAg screening be discontinued in Egyptian blood donors?	Journal of Viral Hepatitis	29(5)	330-339	2022	○
11)	<u>Sugiyama A</u> , Kurisu A, <u>Akita T</u> , <u>Tanaka J</u>	Authors' response to "prevalence and incidence of fatty liver for people who took part in a health checkup in 2008-2019 in Japan"	Liver International	42(6)	1478	2022	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
12)	E B, Ou P, Ouoba S, Hussain Md RA, Ko K, Nagashima S, <u>Sugiyama A</u> , <u>Akita T</u> , <u>Tanaka I</u>	Prevalence and genotype distribution of viral hepatitis B in Cambodia between 1990 and 2020: A Systematic Review and Meta-analysis	Archives of Public Health	80(1)	119	2022	○
13)	<u>Sugiyama A</u> , Miwata K, Kitahara Y, Okimoto M, Abe K, Ouoba S, <u>Akita T</u> , Tanimine N, Ohdan H, Kubo T, Nagasawa A, Nakanishi T, Takafuta T, <u>Tanaka I</u>	Long COVID occurrence in COVID-19 survivors	Scientific Reports	12(1)	6039	2022	
14)	<u>Sugiyama A</u> , Kurisu A, E B, Ouoba S, Ko K, Rakhimov A, <u>Akita T</u> , Harakawa T, Sako T, Koshiyama M, Kumada T, <u>Tanaka I</u>	Distribution of FIB-4 index in the general population -Analysis of 75,666 residents who underwent health checkups-	BMC gastroenterology	22(1)	241	2022	○
15)	<u>Toyoda H</u> , <u>Atsukawa M</u> , Uojima H, Nozaki A, Takaguchi K, Hiraoka A, Itobayashi E, Watanabe T, Matsuura K, Shimada N, Abe H, Tsuji K, Itokawa N, Mikami S, Ishikawa T, Oikawa T, Yasuda S, Chuma M, <u>Tanaka I</u>	The Impact of cirrhosis and history of hepatocellular carcinoma on all-cause mortality after eradication of hepatitis C virus in patients with chronic hepatitis C	Gastro Hep Advances	1(4)	508	2022	○
16)	Kaneko S, Kurosaki M, Kurisu A, <u>Akita T</u> , <u>Tanaka I</u> , Kanto T	Impact of antiviral therapy for disease progression and non-invasive liver fibrosis index in patients with chronic hepatitis C: Markov chain model analysis	Hepatology Research	52(8)	665-676	2022	○
17)	Tada T, Kumada T, Matono T, Nakamura S, Sue M, Matuo Y, Masahiro T, Iijima H, <u>Tanaka I</u>	Characteristics of hepatocellular carcinoma in patients with hepatitis C virus who received direct-acting antiviral therapy and achieved sustained virological response: The impact of a hepatologist on surveillance	Journal of gastroenterology and hepatology open	6(7)	462-469	2022	○
18)	Ito M, <u>Sugiyama A</u> , Mino M, Kodama M, Nagaoki Y, Abe K, Imada H, Ouoba S, E B, Ko K, <u>Akita T</u> , Harakawa T, Sako T, Chayama K, <u>Tanaka I</u>	Prevalence of Helicobacter pylori infection in the general population evaluated by a resident-register-based epidemiological study	Journal of Gastroenterology	57(8)	540-546	2022	
19)	Kumada T, <u>Toyoda H</u> , Yasuda S, Ito T, Tsuji K, Fujioka S, Hiraoka A, Kariyama K, Nouse K, Ishikawa T, Tamai T, Tada T, <u>Tanaka I</u>	Factors linked to hepatocellular carcinoma development beyond 10 years after viral eradication in patients with hepatitis C virus	Journal of Viral Hepatitis	29(10)	919-929	2022	○
20)	<u>Tanaka I</u> , Sun J	Special Issue:The Changing Epidemiology of Liver Disease in Asia	Liver International	42(9)	1926-2116	2022	○
21)	Sun J, <u>Tanaka I</u> , Valenti L	The changing epidemiology of liver diseases in Asia	Liver International	42(9)	1926-1929	2022	○
22)	<u>Sugiyama A</u> , Kurisu A, Nagashima S, Hando K, Saipova K, Akhmedova S, Abe K, Imada H, Hussain Md RA, Ouoba S, E B, Ko K, <u>Akita T</u> , Yamazaki S, Yokozaki M, <u>Tanaka I</u>	Seroepidemiological study of factors affecting anti-spike IgG antibody titers after a two-dose mRNA COVID-19 vaccination in 3744 healthy Japanese volunteers	Scientific Reports	12(1)	16294	2022	
23)	Hussain Md RA, Hiebert L, <u>Sugiyama A</u> , Ouoba S, Bunthen E, Ko K, <u>Akita T</u> , Kaneko S, Kanto T, Ward JW, <u>Tanaka I</u>	Effect of COVID-19 on hepatitis B and C virus countermeasures: Hepatologist responses from nationwide survey in Japan	Hepatology Research	52(11)	899-907	2022	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
24)	<u>Sugiyama A</u> , Okada F, Abe K, Imada H, Ouoba S, E B, Hussain M RA, Ohisa M, Ko K, Nagashima S, <u>Akita T</u> , Yamazaki S, Yokozaki M, Kishita E, <u>Tanaka I</u>	A longitudinal study of anti-SARS-CoV-2 antibody seroprevalence in a random sample of the general population in Hiroshima in 2020	Environmental Health and Preventive Medicine	27(0)	30	2022	
25)	Eto S, Nukui Y, Tsumura M, Nakagama Y, Kashimada K, Mizoguchi Y, Utsumi T, Taniguchi M, Sakura F, Noma K, Yoshida Y, Ohshimo S, Nagashima S, Okamoto K, Endo A, Imai K, Kanegane H, Ohnishi H, Hirata S, Sugiyama E, Shime N, Ito M, Ohge H, Kido Y, Bastard P, Casanova JL, Ohara O, <u>Tanaka I</u> , Morio T, Okada S	Neutralizing type I interferon autoantibodies in Japanese patients with severe COVID-19	Journal of clinical immunology	42(7)	1360-1370	2022	
26)	Omori K, Shigemoto N, Kitagawa H, Nomura T, Kaiki Y, Miyaji K, <u>Akita T</u> , Kobayashi T, Hattori M, Hasunuma N, <u>Tanaka I</u> , Ohge H	Virtual reality as a learning tool for improving infection control procedures	American journal of infection control	S0196-6553(22)	00465-5	2022	
27)	Okamoto Y, Hiyama T, Miyake Y, Yoshino A, Miyauchi S, <u>Tanaka I</u>	Attitudes and behavior toward COVID-19 vaccination in Japanese university students: A cross-sectional study	Vaccines	10(6)	863	2022	
28)	Kumada T, <u>Toyoda H</u> , Yasuda S, Ogawa S, Gotoh T, Tada T, Ito T, Sumida Y, <u>Tanaka I</u>	Combined ultrasound and magnetic resonance elastography predict hepatocellular carcinoma after hepatitis C virus eradication	Hepatology Research	52(11)	957-967	2022	○
29)	Kumada T, <u>Toyoda H</u> , Yasuda S, Ogawa S, Gotoh T, Ito T, Tada T, <u>Tanaka I</u>	Liver stiffness measurements by 2D shear-wave elastography: Effect of steatosis on fibrosis evaluation	American journal of roentgenology	219(4)	604-612	2022	○
30)	Ishii S, <u>Sugiyama A</u> , Ito N, Miwata K, Kitahara Y, Okimoto M, Kurisu A, Abe K, Imada H, <u>Akita T</u> , Kubo T, Nagasawa A, Nakanishi T, Takafuta T, Kuwabara M, <u>Tanaka I</u>	The role of discrimination in the relation between COVID-19 sequelae, psychological distress, and work impairment in COVID-19 survivors	Scientific reports	12(1)	22218	2022	
31)	Nagaoki Y, <u>Sugiyama A</u> , Mino M, Kodama H, Abe K, Imada H, Ouoba S, E B, Ko K, <u>Akita T</u> , Sako T, Kumada T, Chayama K, <u>Tanaka I</u>	Prevalence of fatty liver and advanced fibrosis by ultrasonography and FibroScan in a general population random sample	Hepatology Research	52(11)	908-918	2022	○
32)	Kumada T, Ogawa S, Goto T, <u>Toyoda H</u> , Yasuda S, Ito T, Yasuda E, <u>Akita T</u> , <u>Tanaka I</u>	Intra-individual comparisons of the ultrasound-guided attenuation parameter and the magnetic resonance imaging-based proton density fat fraction using bias and precision statistics	Ultrasound in Medicine and Biology	48(8)	1537-1546	2022	
33)	<u>Toyoda H</u> , Yasuda S, Moriya A, Itobayashi E, Uojima H, Watanabe T, <u>Atsukawa M</u> , Arai T, Ishikawa T, Mikami S, Hiraoka A, Tsuji K, Oikawa T, Tsubota A, Nozaki A, Chuma M, Abe H, Shima T, Kumada T, <u>Tanaka I</u>	Misunderstanding of hepatitis C virus (HCV) infection status by non-specialized medical doctors in patients who achieved sustained virologic response to anti-HCV therapy	Journal of Infection and Chemotherapy	28(9)	1231-1234	2022	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
34)	児玉美穂、原鐵晃、頼英美、児玉尚志、大森百合子、秋田智之、 <u>田中純子</u>	腹腔鏡下卵巣開孔術後の卵巣発育の有無は、術前 LH/FSH 比と卵巣単位体積当たり開孔数によって推測することができる Prediction of follicle development after laparoscopic ovarian drilling by the pre-operative LH/FSH ratio and number of drillings per ovarian unit volume.	日本産科婦人科内視鏡学会雑誌	38(1)	19-25	2022	
35)	<u>田中純子</u>	わが国における肝臓の動向	肝がん白書		8-14	2022	○
36)	杉山文、栗栖あけみ、熊田卓、 <u>田中純子</u>	大規模レセプトデータ解析による NASH 診断前生検実施割合の実態把握	肝臓	63(4)	211-213	2022	○
37)	Yokokawa H, Shinohara M, Teraoka Y, Imamura M, Nakamura N, Watanabe N, Date T, <u>Aizaki H</u> , Iwamura T, Narumi H, Chayama K, <u>Wakita T</u>	Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants.	PLoS One	22		2022	
38)	Ando T, <u>Aizaki H</u> , Sugiyama M, Date T, Hayashi K, Ishigami M, Katano Y, Goto H, Mizokami M, Muramatsu M, Kuroda M, <u>Wakita T</u>	Independent evolution of multi-dominant viral genome species observed in a hepatitis C virus carrier.	Biochem Biophys Rep	29		2022	
39)	Li X, Ito M, Aoyagi H, Murayama A, <u>Aizaki H</u> , Fukasawa M, Kato T, <u>Wakita T</u> , Suzuki T	Development and Use of a Kinetic and Real-Time Monitoring System to Analyze the Replication of Hepatitis C Virus.	Int J Mol Sci	5		2022	
40)	Kobayashi C, Watanabe Y, Oshima M, Hirose T, Yamasaki M, Iwamoto M, Iwatsuki M, Asami Y, Kuramochi K, Wakae K, <u>Aizaki H</u> , Muramatsu M, Sureau C, Sunazuka T, Watashi K	Fungal Secondary Metabolite Exophilic Acid Selectively Inhibits the Entry of Hepatitis B and D Viruses.	Viruses	6		2022	
41)	Yato K, Matsuda M, Watanabe N, Watashi K, <u>Aizaki H</u> , Kato T, Tamura K, <u>Wakita T</u> , Muramatsu M, Suzuki R	Induction of neutralizing antibodies against hepatitis C virus by a subviral particle-based DNA vaccine.	Antiviral Res	199		2022	
42)	Suzuki H, Iwamoto H, Seki T, Nakamura T, Masuda A, Sakaue T, Tanaka T, Imamura Y, Niizeki T, Nakano M, Shimose S, Shirono T, Noda Y, Kamachi N, Sakai M, Morita K, Nakayama M, Yoshizumi T, Kuromatsu R, Yano H, Cao Y, <u>Koga H</u> , <u>Torimura T</u>	Tumor-derived insulin-like growth factor-binding protein-1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors.	Cancer Commun (Lond)	43(4)		2023	
43)	Shimose S, Hiraoka A, Casadei-Gardini A, Tsutsumi T, Nakano D, Iwamoto H, Tada F, Rimini M, Tanaka M, Torimura T, Suga H, Ohama H, Burgio V, Niizeki T, Moriyama E, Suzuki H, Shirono T, Noda Y, Kamachi N, Nakano M, Kuromatsu R, <u>Koga H</u> , Kawaguchi T	The beneficial impact of metabolic dysfunction-associated fatty liver disease on lenvatinib treatment in patients with non-viral hepatocellular carcinoma.	Hepatol Res	53(2)	104-115	2023	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
44)	Iwamoto H, Niizeki T, Nagamatsu H, Ueshima K, Tani J, Kuzuya T, Kasai K, Kooka Y, Hiraoka A, Sugimoto R, Yonezawa T, Tanaka S, Deguchi A, Shimose S, Shirono T, Sakai M, Suzuki H, Moriyama E, <u>Koga H, Torimura T</u> , Kawaguchi T, New Fp Study Group, Kurume Liver Cancer Study Group Of Japan	The Clinical Impact of Hepatic Arterial Infusion Chemotherapy New-FP for Hepatocellular Carcinoma with Preserved Liver Function.	Cancers (Basel)	14(19)	4873	2022	
45)	Shimose S, Hiraoka A, Tanaka M, Iwamoto H, Tanaka T, Noguchi K, Aino H, Yamaguchi T, Itano S, Suga H, Niizeki T, Moriyama E, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Kawaguchi T, Kuromatsu R, <u>Koga H, Torimura T</u>	Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma.	Sci Rep	12(1)	17018	2022	
46)	Shimose S, Hiraoka A, Casadei-Gardini A, Tsutsumi T, Nakano D, Iwamoto H, Tada F, Rimini M, Tanaka M, Torimura T, Suga H, Ohama H, Burgio V, Niizeki T, Moriyama E, Suzuki H, Shirono T, Noda Y, Kamachi N, Nakano M, Kuromatsu R, <u>Koga H</u> , Kawaguchi T	The beneficial impact of metabolic dysfunction-associated fatty liver disease on lenvatinib treatment in patients with non-viral hepatocellular carcinoma.	Hepatol Res	53(2)	104-115	2022	
47)	Tanaka T, Suzuki H, Miwa K, Ushijima T, Nagasu S, Fukahori M, Ishii K, Nakamura T, Iwamoto H, Masuda A, Sakaue T, <u>Koga H</u> , Akagi Y, Murotani K, <u>Torimura T</u>	Hyperlipidemia as a risk factor for Trousseau syndrome-related cerebral infarction in patients with advanced gastrointestinal cancer.	Oncol Lett	24(3)	318	2022	
48)	Shirono T, Iwamoto H, Niizeki T, Shimose S, Kajiwaru A, Suzuki H, Kamachi N, Noda Y, Okamura S, Nakano M, Kuromatsu R, Murotani K, <u>Koga H, Torimura T</u>	Durable complete response is achieved by balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. . 2022 Sep;.	Hepatol Commun	6(9)	2594-2604	2022	
49)	Arinaga-Hino T, Ide T, Akiba J, Suzuki H, Kuwahara R, Amano K, Kawaguchi T, Sano T, Inoue E, <u>Koga H</u> , Mitsuyama K, <u>Koga Y, Torimura T</u>	Growth differentiation factor 15 as a novel diagnostic and therapeutic marker for autoimmune hepatitis.	Sci Rep	12(1)	8759	2022	
50)	Suzuki H, Arinaga-Hino T, Sano T, Mihara Y, Kusano H, Mizuochi T, Togawa T, Ito S, Ide T, Kuwahara R, Amano K, Kawaguchi T, Yano H, Kage M, <u>Koga H, Torimura T</u>	Case Report: A Rare Case of Benign Recurrent Intrahepatic Cholestasis-Type 1 With a Novel Heterozygous Pathogenic Variant of ATP8B1.	Front Med (Lausanne)	9	891659	2022	
51)	Kuromatsu R, Ide T, Okamura S, Noda Y, Kamachi N, Nakano M, Shirono T, Shimose S, Iwamoto H, Kuwahara R, Arinaga-Hino T, Niizeki T, Zaizen Y, Takaki H, Shirachi M, <u>Koga H, Torimura T</u>	Hepatitis C Virus Elimination Using Direct Acting Antivirals after the Radical Cure of Hepatocellular Carcinoma Suppresses the Recurrence of the Cancer.	Cancers (Basel)	14(9)	2295	2022	
52)	Nakano D, Kawaguchi T, Tsutsumi T, Hayakawa M, Yoshio S, <u>Koga H, Torimura T</u>	Effects of SGLT2 inhibitor on tumor-releasing chemokines/cytokines in Hep3B and Huh7 cells.	JGH Open	6(4)	270-273	2022	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
53)	Iwamoto H, Shimose S, Niizeki T, <u>Koga H, Torimura T</u>	Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma.	Clin Mol Hepatol	28(3)	575-579	2022	
54)	Suzuki H, Sano T, Shimasaki Y, Yamaguchi M, Ide T, Arinaga-Hino T, Kuwahara R, Amano K, Oshima K, Nagafuji K, Ida H, <u>Koga H, Torimura T</u>	TAFRO Syndrome That Responded to Prednisolone-only Treatment: Evaluating Changes in IL-6.	Intern Med	61(19)	2967-2972	2022	
55)	Suzuki H, Niizeki T, Shirono T, Koteda Y, Kinjo Y, Mizukami N, Koda M, Ota S, Nakano M, Okamura S, Iwamoto H, Shimose S, Noda Y, Kamachi N, Kajiwaru A, Suda K, Akiba J, Yano H, Kuromatsu R, <u>Koga H, Torimura T</u>	Robust Effect of Hepatic Arterial Infusion Chemotherapy and Radiation Therapy on Hepatocellular Carcinoma Arising from Fontan-associated Liver Disease.	Intern Med	61(8)	1145-1150	2022	
56)	Shirono T, <u>Koga H</u> , Niizeki T, Nagamatsu H, Iwamoto H, Shimose S, Nakano M, Okamura S, Noda Y, Kamachi N, Kuromatsu R, Ogo E, <u>Torimura T</u>	Usefulness of a novel transarterial chemoinfusion plus external-beam radiation therapy for advanced hepatocellular carcinoma with tumor thrombi in the inferior vena cava and right atrium: Case study.	Cancer Rep (Hoboken)	5(8)	e1539	2022	
57)	Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kaibori M, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Kosaka H, Hiasa Y, Kudo M	Relationship of atezolizumab plus bevacizumab treatment with muscle volume loss in unresectable hepatocellular carcinoma patients- multicenter analysis.	Liver Cancer			in press	
58)	<u>Toyoda H</u> , Kariyama K, Hiraoka A	Rising incidence and poor survival in patients with nonviral HCC – better HCC surveillance and treatment for alcohol-associated and non-alcohol fatty liver diseases are needed. authors' reply.	Aliment Pharmacol Ther	57	363-364	2023	
59)	Fujii H, Iwaki M, Hayashi H, <u>Toyoda H</u> , Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Yamamura S, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Kawada N, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)	Clinical outcomes in biopsy-proven nonalcoholic fatty liver disease patients: a multicenter registry-based cohort study.	Clin Gastroenterol Hepatol	21	370-379	2023	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
60)	<u>Toyoda H</u> , Kariyama K, Hiraoka A, Tsuji K, Ishikawa T, Hatanaka T, Naganuma A, Yasuda S, Nouse K, Kakizaki S, Kumada T, Innes H, Johnson PJ	Improved survival of viral HCC but non-viral HCC from 2000 to 2020: a multicenter cohort study of 6,007 patients from high-volume academic centers in Japan.	Aliment Pharmacol Ther	56	694-701	2022	
61)	<u>Toyoda H</u> , Kariyama K, Hiraoka A	Non-viral hepatocellular carcinoma surveillance – an increasingly severe public health issue. – authors’ reply.	Aliment Pharmacol Ther	56	750-751	2022	
62)	Matsushima-Nishiwaki R, <u>Toyoda H</u> , Maeda A, Kaneoka Y, Kumada T, Kozawa O	Correlation between the complex of small heat shock proteins (HSPBs) and the progression in patients with hepatocellular carcinoma.	Arch Biochem Biophys	732	109461	2022	
63)	Johnson PJ, Innes H, Hughes DM, Kalyuzhnyy A, Kumada T, <u>Toyoda H</u>	Evaluation of the aMAP score for hepatocellular carcinoma surveillance: a realistic opportunity to risk stratify.	Br J Cancer	127	1263-1269	2022	
64)	Yamamoto T, Ito T, Hase, T, Ishigami, M, Mizuno K, Yamamoto K, Imai N, Ishizu Y, Honda T, Shibata H, Hatta T, Yogo N, Yasuda S, <u>Toyoda H</u> , Abe T, Kawashima H, Hashimoto N, Fujishiro M	Immune-related liver injury is a poor prognostic factor in patients with non-small cell lung cancer treated with immune checkpoint inhibitors.	Cancer Invest	40	189-198	2022	
65)	Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y	Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: a multicenter analysis.	Cancer Med	11	3796-3808	2022	
66)	Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Kudo M	Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: early clinical experience.	Cancer Rep	5	e1464	2022	

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
67) Park J, Le AK, Tseng TC, Yeh ML, Jun DW, Trinh H, Wong GLH, Chen CH, Peng CY, Kim SE, Oh H, Kwak MS, Cheung KS, Toyoda H , Hsu YC, Jeong JY, Yoon EL, Ungtrakul T, Zhang J, Xie Q, Ahn SB, Enomoto M, Shim JJ, Cunningham C, Jeong SW, Cho YK, Ogawa E, Huang R, Lee DH, Takahashi H, Tsai PC, Huang CF, Dai CY, Tseng CH, Yasuda S, Kozuka R, Li J, Wong C, Wong CC, Zhao C, Hoang J, Eguchi Y, Wu C, Tanaka Y, Gane E, Tanwandee T, Cheung R, Yuen MF, Lee HS, Yu ML, Kao JH, Yang HL, Nguyen MH	Progression rates by age, sex, treatment, and disease activity by AASLD and EASL criteria: data for precision medicine..	Clin Gastroenterol Hepatol	20	874-885	2022	
68) Imajo K, Toyoda H , Yasuda S, Suzuki Y, Sugimoto K, Kuroda H, Yasui Y, Kurosaki M, Izumi N, Nakajima A, Kumada T	Utility of ultrasound-guided attenuation parameter for the quantification of steatosis with reference to MRI-based proton density fat fraction: a multicenter, prospective study.	Clin Gastroenterol Hepatol	20	2533-2541	2022	
69) Tada T, Kumada T, Toyoda H , Nakamura S, Endo Y, Kaneoka Y, Hiraoka A, Joko K, Hirooka M, Hiasa Y	A validation study of combined resection and ablation therapy for multiple hepatocellular carcinoma.	Clin Radiol	77	114-120	2022	
70) Chuma M, Yokoo H, Hiraoka A, Ueda K, Yokoyama T, Tsuji K, Shimada N, Uojima H, Kobayashi S, Hattori N, Okubo T, Atsukawa M , Ishikawa T, Takaguchi K, Tsutsui A, Toyoda H , Tada T, Saito Y, Hirose S, Tanaka T, Takeda K, Otani M, Sekikawa Z, Watanabe T, Hidaka H, Morimoto M, Numata K, Kagawa T, Sakamoto M, Kumada T, Maeda S	Identification of CT values that could be predictive of necrosis (N-CTav) in hepatocellular carcinoma after lenvatinib treatment.	Curr Oncol	29	3259-3271	2022	
71) Kam LY, Huang DQ, Teng MLP, Takahashi H, Tanaka K, Yasuda S, Fung J, Lee TY, Hyogo H, Ono M, Saruwatari J, Oniki K, Yeo YH, Barnett S, Henry L, Li J, Zou B, Cheung RC, Kumada T, Yuen MF, Eguchi Y, Toyoda H , Nguyen MH	Clinical profiles of Asians with NAFLD: a systematic review and meta-analysis.	Dig Dis	40	734-744	2022	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
72)	Rimini M, Rimassa L, Ueshima K, Burgio V, Shimose S, Tada T, Suda G, Yoo C, Cheon J, Pinato DJ, Lonardi S, Scartozzi M, Iavarone M, Di Costanzo GG, Marra F, Solda C, Tamburini E, Piscaglia F, Masi G, Cabibbo G, Foschi FG, Silletta M, Pressiani T, Nishida N, Iwamoto H, Sakamoto N, Ryoo BY, Chon HJ, Claudia F, Niizeki T, Sho T, Kang B, Antonio D, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimur T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Pedica F, De Cobelli F, Ratti F, Alighetti L, Kudo M, Cascinu S, Casadei-Gardini A	Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.	ESMO Open	7	100591	2022	
73)	Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y	Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis.	Eur J Gastroenterol Hepatol	34	698-706	2022	
74)	Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Aoki T, Koizumi Y, Nakamura S, Joko K, Hiasa Y, Kudo M	Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis.	Eur J Gastroenterol Hepatol	34	857-864	2022	
75)	Kariyama K, Kawanaka M, Nouse K, Hiraoka A, <u>Toyoda H</u> , Tada T, Ishikawa T, Wakuta A, Miyake N, Murakami S, Shiota S, Kumada T	Fibrosis-3 index: a new score to predict liver fibrosis in patients with nonalcoholic fatty liver disease without age as a factor.	Gastro Hep Adv	1	1108-1113	2022	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
76)	Korenaga M, Murata K, Izumi N, Tamaki N, Yokosuka O, Takehara T, Sakamoto N, Suda G, Nishiguchi S, Enomoto H, Ikeda F, Yanase M, <u>Toyoda H</u> , Genda T, Umemura T, Yatsushashi H, Yamasaki K, Ide T, Toda N, Kanda T, Nirei K, Ueno Y, Haga H, Nishigaki Y, Nakane K, Omata M, Mochizuki H, Aoki Y, Imamura M, Kanto T, Mizokami M	No increased risk of hepatocellular carcinoma after eradication of hepatitis C virus by direct-acting antivirals, compared with interferon-based therapy.	Global Health Med	4	216-224	2022	○
77)	Sapena V, Enea M, Torres F, Celsa C, Rios J, Rizzo GEM, Nahon P, Marino Z, Tateishi R, Minami T, Sangiovanni A, Fornis X, <u>Toyoda H</u> , Brillanti S, Conti F, Degasperis E, Yu ML, Tsai PC, Jean K, El Kassas M, Shousha HI, Abdelaziz AO, Zavaglia C, Nagata H, Nakagawa M, Asahina Y, Singal AG, Murphy CC, Kohla M, Masetti C, Dufour JF, Merchante N, Cavalletto L, Chemello L, Pol S, Crespo J, Calleja JL, Villani R, Serviddio G, Zanetto A, Shalaby S, Russo FP, Bielen R, Trevisani F, Camma C, Bruix J, Cabibbo G, Reig M	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis.	Gut	71	593-604	2022	○
78)	Tamaki N, Kurosaki M, Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H, Kimura H, Yagisawa H, Marusawa H, Kondo M, Kojima Y, Yoshida H, Uchida Y, Tada T, Nakamura S, Yasuda S, <u>Toyoda H</u> , Loomba R, Izumi N	Hepatocellular carcinoma risk assessment for patients with advanced fibrosis after eradication of hepatitis C virus.	Hepatol Commun	6	461-472	2022	○
79)	Reveron-Thornton RF, Teng MLP, Lee EY, Tran A, Vajanaphanich S, Tan EX, Nerurkar SN, Ng RX, Teh R, Tripathy DP, Ito T, Tanaka T, Miyake N, Zou B, Wong C, <u>Toyoda H</u> , Esquivel CO, Bonham CA, Nguyen MH, Huang DQ	Global and regional long-term survival following resection for HCC in the recent decade: a meta-analysis of 110 studies.	Hepatol Commun	6	1813-1826	2022	
80)	Kawata K, <u>Atsukawa M</u> , Ohta K, Chida T, Noritake H, Arai T, Iwakiri K, Yasuda S, <u>Toyoda H</u> , Okubo T, Hiraoka A, Watanabe T, Uojima H, Nozaki A, Tani J, Morishita A, Kageyama F, Sasada Y, Nagasawa M, Matsushita M, Oyaizu T, Mikami S, <u>Ikegami T</u> , Abe H, Matsuura K, Tanaka Y, Tsubota A	Mac-2-binding protein glycan isomer predicts all malignancies post-sustained virological response in chronic hepatitis C.	Hepatol Commun	6	1855-1869	2022	○
81)	<u>Toyoda H</u> , <u>Atsukawa M</u>	The best predictive model for post-SVR HCC: can it be universal?	Hepatol Int	16	728	2022	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
82)	Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Shimada N, Kawata K, Kosaka H, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Kaibori M, Iijima H, Hiasa Y, Kumada T	Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study.	Hepatol Int	16	1150-1160	2022	
83)	Hsu YC, Jun DW, Peng CY, Yeh ML, Trinh H, Wong GL, Kim SE, Chen CH, Oh H, Lin CH, Trinh L, Wong VW, Yoon E, Ahn SB, Huang D, Cho YK, Jeong JY, Jeong SW, Kim HS, Xie Q, Liu L, Riveiro-Barciela M, Tsai PC, Accarino EV, <u>Toyoda H</u> , Enomoto M, Preda C, Marciano S, Hoang J, Huang CF, Kozuka R, Yasuda S, Istratescu D, Lee DH, Su JY, Huang YT, Huang JF, Dai CY, Chuang WL, Yuen MF, Gadano A, Cheung R, Lim SG, Buti M, Yu ML, Nguyen MH	Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort.	Hepatol Int	16	1297-1307	2022	
84)	<u>Toyoda H</u> , Yasuda S, Shiota S, Kumada T	Long-term persistence of hepatocarcinogenic potential of a non-hypervascular hypointense nodule on EOB-MRI after the eradication of hepatitis C virus.	Hepatol Res	52	128-132	2022	○
85)	Kumada T, <u>Toyoda H</u> , Yasuda S, Ito T, <u>Tanaka I</u>	Mortality of inactive hepatitis B virus carriers in Japan is similar to that of the general population.	Hepatol Res	52	81-92	2022	
86)	Shiha G, Soliman R, Mikhail NNH, Alswat K, Abdo AA, Sanai FM, Derbala MFM, Ormeci N, Dalekos GN, Al-Busafi SA, Hamoudi W, Sharara AI, Zaky S, El-Raey F, Mabrouk MS, Marzouk SY, <u>Toyoda H</u>	Development and multicenter validation of FIB-6; a novel, machine-learning, simple bedside score to rule out liver cirrhosis and compensated advanced chronic liver disease in CHC patients.	Hepatol Res	52	165-175	2022	○
87)	Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Kudo M	Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to 7 criteria –multicenter analysis.	Hepatol Res	52	308-316	2022	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
88)	<u>Atsukawa M</u> , Tsubota A, Kondo C, <u>Toyoda H</u> , Nakamura M, Takaguchi K, Watanabe T, Hiraoka A, Uojima H, Ishikawa T, Iwasa M, Tada T, Nozaki A, Chuma M, Fukunishi S, Asano T, Ogawa C, Abe H, Kato K, Hotta N, Shima T, Matsuura K, Mikami S, Tachi Y, Fujioka S, Okubo H, Shimada N, Tani J, Morishita A, Hidaka I, Moriya A, Tsuji K, Akahane T, Okubo T, Arai T, Kitamura M, Morita K, Kawata K, Tanaka Y, Kumada T, Iwakiri K, KTK49 Liver Study Group	Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis.	Hepatol Res	52	235-246	2022	
89)	Hatanaka T, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Kumada T	Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a landmark analysis.	Hepatol Res	52	462-470	2022	
90)	Tanaka T, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Kaibori M, Hiasa Y, Kudo M, Kumada T	Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice.	Hepatol Res	52	773-783	2022	
91)	Rimini M, Kang W, Burgio V, Persano M, Aoki T, Shimose S, Tada T, Kumada T, Sho T, Lai E, Celsa C, Campani C, Tonnini M, Tamburini E, Hiraoka A, Takaguchi K, Nishida N, Iwamoto H, Itobayashi E, Tsuji K, Sakamoto N, Ishikawa T, <u>Toyoda H</u> , Kudo M, Kawaguchi T, Hatanaka T, Nouse K, Suda G, Cabibbo G, Marra F, Della Corte A, Ratti F, Pedica F, De Cobelli F, Aldrighetti L, Scartozzi M, Cascinu S, Casadei Gardini A	Validation of the easy-to-use lenvatinib prognostic (LEP) index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib.	Hepatol Res	52	1050-1059	2022	
92)	<u>Toyoda H</u>	Sofosbuvir/velpatasvir and glecaprevir/pibrentasvir: how should we choose among these two last regimens?	Hepatol Res	52	815-816	2022	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
93)	Kawamura N, Imajo K, Kalutkiewicz KJ, Nagai K, Iwaki M, Kobayashi T, Nogami A, Honda Y, Kessoku T, Ogawa Y, Higurashi T, Hosono K, Takahashi H, Yoneda M, Saito S, Aishima S, <u>Toyoda H</u> , Hayashi H, Sumida Y, Ehman RL, Nakajima A	Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease.	Hepatology	76	186-195	2022	
94)	Johnson P, Pinato DJ, Kalyuzhnyy A, <u>Toyoda H</u>	Breaking the Child-Pugh dogma in hepatocellular carcinoma.	J Clin Oncol	40	2078-2082	2022	
95)	Nishida N, Yamakawa M, Shiina T, Mekada Y, Nishida M, Sakamoto N, Nishimura T, Iijima H, Hirai T, Takahashi K, Sato M, Tateishi R, Ogawa M, Mori H, Kitano M, <u>Toyoda H</u> , Ogawa C, Kudo M, JSUM AI investigators	Development of artificial intelligence (AI) for the ultrasonographic diagnosis of liver tumor and comparison of diagnostic accuracy with AI versus human experts.	J Gastroenterol	57	309-321	2022	
96)	Kariyama K, Hiraoka A, Kumada T, Yasuda S, <u>Toyoda H</u> , Tsuji K, Hatanaka T, Kakizaki S, Naganuma A, Tada T, Takaguchi K, Itobayashi E, Ishikawa T, Shimada N, Tsutsui A, Nagano T, Imai M, Nakamura S, Wakuta A, Miyake N, Shiota S, Nouse K	Chronological change in serum albumin as a good prognostic factor in patients with hepatocellular carcinoma treated with lenvatinib: proposal of albumin simplified grading based on the modified albumin-bilirubin score (ALBS grade).	J Gastroenterol	57	581-586	2022	
97)	Sakamoto K, Ito K, Yotsuyanagi H, Yatsuhashi H, Tanaka Y, Hige S, Takikawa Y, Ueno Y, Yamamoto K, Imazeki F, Inoue J, Kurosaki M, Umemura T, <u>Toyoda H</u> , Mita E, Michitaka K, Maeshiro T, Yamada N, Suetsugu A, Kawanaka M, Seko Y, Matsuura K, Okumura A, Fukuzawa Y, Sugiyama M, Mizokami M, Yoneda M	Trends of hepatitis B virus genotype distribution in chronic hepatitis B patients in Japan.	J Gastroenterol	57	971-980	2022	
98)	Seko Y, Kawanaka M, Fujii H, Iwaki M, Hayashi H, <u>Toyoda H</u> , Oeda S, Hyogo H, Morishita A, Munekage K, Kawata K, Yamamura S, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Okanoue T, Itoh Y, Nakajima A	Age-dependent effects of diabetes and obesity on liver-related events in nonalcoholic fatty liver disease: subanalysis of CLIONE in Asia.	J Gastroenterol Hepatol	37	2313-2320	2022	
99)	Shiha G, Soliman R, Mikhail NNH, Carrat F, Azzi J, Ganne-Carrie N, <u>Toyoda H</u> , Uojima H, Nozaki A, Takaguchi K, Hiraoka A, <u>Atsukawa M</u> , Abe H, Matsuura K, Mikami S, Watanabe T, Tsuji K, Ishikawa T, Suri V, Osinusi A, Ni L, Zou J, Sarin S, Kumar M, Jalal PK, Hashim MA, Hassan M, Lopez SA, Banares R, Ahumada AM, Mousa N, Eslam M, Waked I	International multicenter validation of GES score for HCC risk stratification in chronic hepatitis C patients.	J Viral Hepat	29	807-816	2022	○
100)	<u>Toyoda H</u> , Johnson PJ	The ALBI score: from liver function in patients with HCC to a general measure of liver function.	JHEP Rep	4(10)	100557	2022	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
101)	Casadei-Gardini A, Rimini M, Kudo M, Shimose S, Tada T, Suda G, Goh MJ, Jefremow A, Scartozzi M, Cabibbo G, Campani C, Tamburini E, Tovoli F, Ueshima K, Aoki T, Iwamoto H, Torimura T, Kumada T, Hiraoka A, <u>Atsukawa M</u> , Itobayashi E, <u>Toyoda H</u> , Sakamoto N, Sho T, Kang W, Siebler J, Neurath MF, Burgio V, Cascinu S	REal life study of LEnVAtiNib therapy for HepAtocellular carcinoma: RELEVANT study.	Liver Cancer	11	527-539	2022	
102)	Hiraoka A, Kumada T, Kariyama K, <u>Toyoda H</u> , Yasuda S, Tsuji K, Hatanaka T, Kakizaki S, Naganuma A, Ishikawa T, Tada T, Takaguchi K, Itobayashi E, Shimada N, Tanaka T, Tsutsui A, Nagano T, Imai M, Nakamura S, Nouse K, Shibata H	Simple scoring system for predicting TACE unsuitable among intermediate stage hepatocellular carcinoma patients in multiple systemic treatment era.	Oncology	100	65-73	2022	
103)	Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Ohama H, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, Kudo M	Clinical predictor of urinary protein as adverse event associated with atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma.	Oncology	100	645-654	2022	
104)	Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, <u>Atsukawa M</u> , Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, <u>Toyoda H</u> , Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Aoki T, Koizumi Y, Nakamura S, Joko K, Hiasa Y, Kudo M	C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis.	Sci Rep	12(1)	8421	2022	
105)	Kawano T, <u>Atsukawa M</u> , Tsubota A, Shimada N, <u>Toyoda H</u> , Takaguchi K, Tani J, Morishita A, Hiraoka A, Mikami S, Ishikawa T, Okubo H, Watanabe T, Okubo T, Arai T, Hayama K, Itokawa N, Kondo C, Iwakiri K	Shorter pruritus period and milder disease stage are associated with response to nalfurafine hydrochloride in patients with chronic liver disease.	Sci Rep	12	7311	2022	
106)	Kumada T, Ogawa S, Goto T, <u>Toyoda H</u> , Yasuda S, Ito T, Yasuda E, <u>Akita T</u> , <u>Tanaka I</u>	Intra-individual comparisons of the ultrasound-guided attenuation parameter and magnetic resonance imaging-based proton density fat fraction using bias and precision statistics.	Ultrasound Med Biol	48	1537-1546	2022	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
107)	Endo K, Kakisaka K, Kuroda H, <u>Miyasaka A</u> , Takikawa Y, Matsumoto T	Annual changes in grip strength and skeletal muscle mass in chronic liver disease: observational study.	Sci Rep	13	1648 doi: 10.1038/ s41598- 023- 28528- w.	2023	
108)	Endo K, Kuroda H, Oikawa T, Ito Y, Abe T, Kooka Y, Kakisaka K, <u>Miyasaka A</u> , Sugai T, Matsumoto T	Immune Checkpoint Inhibitor-Related Pneumonia in Unresectable Hepatocellular Carcinoma: Two Fatal Cases under Atezolizumab plus Bevacizumab	Liver Cancer	11	527-575	2022	
109)	Endo K, Sato T, Yoshida Y, Kakisaka K, <u>Miyasaka A</u> , Takikawa Y	Viral eradication by direct-acting antivirals does not decrease the serum myostatin level in patients infected with hepatitis C.	Nutrition	101	111699. doi: 10.1016/ j.nut.202 2.11169 9.	2022	
110)	Kakisaka K, Sato T, Wada Y, Ito A, Eto H, Abe H, Kanazawa J, Yusa K, Endo K, Yoshida Y, Oikawa T, Kuroda H, <u>Miyasaka A</u> , Akasaka M, Matsumoto T	Lactulose: A treatment for hyperammonemia in a lysinuric protein-intolerant patient with dynamic blood amino acid concentrations.	Mol Genet Metab Rep	32	100898. doi: 10.1016 /j.ymgm r.2022.1 00898	2022	
111)	Li YY, Kuroki K, <u>Shimakami T</u> , Murai K, Kawaguchi K, Shirasaki T, Nio K, Sugimoto S, Nishikawa T, Okada H, Orita N, Takayama H, Wang Y, Thi Bich PD, Ishida A, Iwabuchi S, Hashimoto S, Shimaoka T, Tabata N, Watanabe-Takahashi M, Nishikawa K, Yanagawa H, Seiki M, Matsushima K, Yamashita T, Kaneko S, Honda M	Hepatitis B virus utilizes a retrograde trafficking route via the trans-Golgi network to avoid lysosomal degradation.	Cell Mol Gastroenterol Hepatol	15(3)	533-558	2023	
112)	Sumiyadorj A, Murai K, <u>Shimakami T</u> , Kuroki K, Nishikawa T, Kakuya M, Yamada A, Wang Y, Ishida A, Shirasaki T, Kawase S, Li YY, Okada H, Nio K, Kawaguchi K, Yamashita T, Sakai Y, Duger D, Mizukoshi E, Honda M, Kaneko S	A single hepatitis B virus genome with a reporter allows the entire viral life cycle to be monitored in primary human hepatocytes.	Hepatol Commun	6(9)	2441-2454	2022	
113)	Shirasaki T, Yamagoe S, <u>Shimakami T</u> , Murai K, Imamura R, Ishii KA, Takayama H, Matsumoto Y, Tajima-Shirasaki N, Nagata N, Shimizu R, Yamanaka S, Abe A, Omura H, Kawaguchi K, Okada H, Yamashita T, Yoshikawa T, Takimoto K, Taharaguchi M, Takatsuka S, Miyazaki Y, Tamai T, Tanabe Y, Kurachi M, Yamamoto Y, Kaneko S, Matsumoto K, Takamura T, Honda M	Leukocyte cell-derived chemotaxin 2 is an antiviral regulator acting through the proto-oncogene MET.	Nat Commun	13(1)	3176	2022	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
114)	島上哲朗, 佐久間 龍太, 川名 克芳, 黄地 薫, 持田 智, 熊田 博光	サブジェノタイプ 1b の C 型慢性肝炎及び C 型代償性肝硬変患者に対するオムビタスビル/パリタプレビル/リトナビル配合錠の特定使用成績調査 国内臨床試験 長期追跡調査.	肝臓	63(7)	319-334	2022	
115)	Katagiri D, <u>Kikuchi K</u>	he Impact and Treatment of COVID-19 in Hemodialysis Patients	J Clin Med	12(3)	838	2023	
116)	<u>Kikuchi K</u> , Nangaku M, Ryuzaki M, Yamakawa T, Yoshihiro O, Hanafusa N, Sakai K, Kanno Y, Ando R, Shinoda T, Wakino S, Nakamoto H, Takemoto Y, Akizawa T	Effectiveness of SARS-CoV-2 vaccines on hemodialysis patients in Japan: A nationwide cohort study.	Ther Apher Dial	27(1)	19-23	2023	
117)	Naito K, <u>Kikuchi K</u> , Watanabe Y, Narita T	Implementation of two novel schemes for patients on dialysis as a response to the COVID-19 surge in Tokyo.	Glob Health Me	4(5)	253-258	2022	
118)	Yoshifuji A, Toda M, Ryuzaki M, <u>Kikuchi K</u> , Kawai T, Sakai K, Oyama E, Koinuma M, Katayama K, Uehara Y, Ohmagari N, Kanno Y, Kon H, Shinoda T, Takano Y, <u>Tanaka J</u> , Hora K, Nakazawa Y, Hasegawa N, Hanafusa N, Hinoshita F, Morikane K, Wakino S, Nakamoto H, Takemoto Y	Investigation for the efficacy of COVID-19 vaccine in Japanese CKD patients treated with hemodialysis	Ren Replace Ther	8(1)	39	2022	
119)	Yoshifuji A, Ryuzaki M, Uehara Y, Ohmagari N, Kawai T, Kanno Y, <u>Kikuchi K</u> , Kon H, Sakai K, Shinoda T, Takano Y, <u>Tanaka J</u> , Hora K, Nakazawa Y, Hasegawa N, Hanafusa N, Hinoshita F, Morikane K, Wakino S, Nakamoto H, Takemoto Y		Committee report: Questionnaire survey on the treatment of COVID-19 in patients receiving dialysis therapyRen Replace Ther	8(1)	18	2022	
120)	Beppu H, Ogawa T, Ishikane M, Kawanishi T, Fukuda T, Sato L, Matsunaga A, Maeda K, Katagiri D, Ishizaka Y, Mitsuya H, Ohmagari N, Yasui F, Kohara M, <u>Kikuchi K</u> , Wakai S	A case of COVID-19 reinfection in a hemodialysis patient: the role of antibody in SARS-CoV-2 infection	CEN Case Rep	9	1-6	2022	
121)	Toda M, Yoshifuji A, <u>Kikuchi K</u> , Komatsu M, Fujii K, Kato A, Kikuchi T, Nakazawa A, Ryuzaki M	Factors associated with SARS-CoV-2 antibody titers and prognosis of breakthrough infection in hemodialysis patients	Clin Exp Nephrol	8	1-10	2022	
122)	<u>Nishina S</u> , Hino K	CD26/DPP4 as a Therapeutic Target in Nonalcoholic Steatohepatitis Associated Hepatocellular Carcinoma	Cancers (Basel)	14(2)	454	2022	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
123)	Okamoto S, Miyano K, Choshi T, Sugisawa N, Nishiyama T, Kotouge R, Yamamura M, Sakaguchi M, Kinoshita R, Tomonobu N, Katase N, Sasaki K, <u>Nishina S</u> , Hino K, Kurose K, Oka M, Kubota H, Ueno T, Hirai T, Fujiwara H, Kawai C, Itadani M, Morihara A, Matsushima K, Kanegasaki S, Robert M Hoffman, Yamauchi A, Kuribayashi F	Inhibition of pancreatic cancer-cell growth and metastasis in vivo by a pyrazole compound characterized as a cell-migration inhibitor by an in vitro chemotaxis assay	Biomed Pharmacother	155	113733. doi: 10.1016/j.biopha.2022.113733.	2022	
124)	Imai K, Takai K, Unome S, Maeda T, Hanai T, Shirakami Y, Suetsugu A, <u>Shimizu M</u>	Sustained virological response is the most effective in preventing hepatocellular carcinoma recurrence after curative treatment in hepatitis C virus-positive patients: A study using decision tree analysis.	Int J Transl Med	3	345-354	2022	
125)	Hanai T, Nishimura K, Miwa T, Maeda T, Nakahata Y, Imai K, Suetsugu A, Takai K, <u>Shimizu M</u>	A shortened stroop test to identify covert hepatic encephalopathy and predict overt hepatic encephalopathy in patients with cirrhosis.	J Gastroenterol	57	981-989	2022	○
126)	Ogiso Y, Hanai T, Nishimura K, Miwa T, Maeda T, Imai K, Suetsugu A, Takai K, <u>Shimizu M</u>	Usefulness of the trabecular bone score in assessing the risk of vertebral fractures in patients with cirrhosis.	J Clin Med	11	1562	2022	
127)	Miwa T, Hanai T, Nishimura K, Maeda T, Ogiso Y, Imai K, Suetsugu A, Takai K, Shiraki M, <u>Shimizu M</u>	Handgrip strength stratifies the risk of covert and overt hepatic encephalopathy in patients with cirrhosis.	J Parenter Enteral Nutr	46	858-866	2022	○
128)	Miwa T, Hanai T, Nishimura K, Sakai Y, Imai K, Suetsugu A, Takai K, Shiraki M, Katsumura N, <u>Shimizu M</u>	Survival benefit of l-carnitine supplementation in patients with cirrhosis.	J Parenter Enteral Nutr	46	1326-1334	2022	○
129)	Miwa T, Hanai T, Sakai Y, Kochi T, Katsumura N, <u>Shimizu M</u>	Mac-2-binding protein glycosylation isomer is useful to predict muscle cramps in patients with chronic liver disease.	Medicine (Baltimore)	101	e31145	2022	○
130)	Miwa T, Hanai T, Nishimura K, Unome S, Maeda T, Ogiso Y, Imai K, Suetsugu A, Takai K, <u>Shimizu M</u>	Usefulness of the Global Leadership Initiative on Malnutrition criteria to predict sarcopenia and mortality in patients with chronic liver disease.	Hepatol Res	52	928-936	2022	○
131)	Miwa T, Hanai T, Nishimura K, Maeda T, Tajirika S, Imai K, Suetsugu A, Takai K, Yamamoto M, <u>Shimizu M</u>	A simple covert hepatic encephalopathy screening model based on blood biochemical parameters in patients with cirrhosis.	PLoS One	17	e0277829	2022	○
132)	Miwa T, Hanai T, Imai K, Takai K, Shiraki M, Hayashi H, Shimizu S, Nishigaki Y, Tomita E, <u>Shimizu M</u>	Effects of rifaximin on circulating albumin structures and serum ammonia levels in patients with liver cirrhosis.	J Clin Med	11	7318	2022	○
133)	Unome S, Imai K, Takai K, Miwa T, Hanai T, Nishigaki Y, Hayashi H, Kochi T, Shimizu S, Nagano J, Iritani S, Suetsugu A, <u>Shimizu M</u>	Changes in ALBI score and PIVKA-II within three months after commencing atezolizumab plus bevacizumab treatment affect overall survival in patients with unresectable hepatocellular carcinoma.	Cancers (Basel)	14	24	2022	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
134)	清水雅仁、今井健二、末次 淳、杉原潤一、富田栄一	各都道府県における肝疾患対策 取り組みの現状	肝臓クリニカ ルアップデート (別冊)	8	221-224	2022	○
135)	Kamada Y, Nakamura T, Isobe S, Hosono K, Suama Y, Ohtakaki Y, Nauchi A, Yasuda N, Mitsuta S, Miura K, Yamamoto T, Hosono T, Yoshida A, Kawanishi I, Fukushima H, Kinoshita M, Umeda A, Kinoshita Y, Fukami K, Miyawaki T, Fujii H, Yoshida Y, Kawanaka M, Hyogo H, Morishita A, Hayashi H, Tobita H, Tomita K, Ikegami T, Takahashi H, Yoneda M, Jun DW, Sumida Y, Okanoue T, Nakajima A	JANIT Forum. SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: An expert review by the JANIT Forum	J Gastroenterol	58(2)	79-97	2023	
136)	Sato M, Akamatsu M, Shima T, Ikegami T, Yanase M, Mikami S, Imamura J, Nakatsuka T, Tateishi R, Yamauchi N, Ushiku T, Okanoue T, Fujishiro M, Koike K	Impact of novel digital therapeutics system on Nonalcoholic steatohepatitis: The NASH App clinical trial	Am J Gastroenterol		doi: 10.1430 9/ajg.00 0000000 0002143	2023	
137)	Monma T, Iwamoto J, Honda A, Ueda H, Kakizaki F, Yara S, Miyazaki T, Ikegami T	Evaluation of the risk of Clostridium difficile infection using a serum bile acid profile	Metabolites	12(4)	331	2022	
138)	Ueda H, Honda A, Miyazaki T, Morishita Y, Hirayama T, Iwamoto J, Nakamoto N, Ikegami T	Sex-, age-, and organ-dependent improvement of bile acid hydrophobicity by ursodeoxycholic acid treatment: a study using a mouse model with human-like bile acid composition	PLoS ONE	17(7)	e027130 8	2022	
139)	Monma T, Iwamoto J, Ueda H, Tamamushi M, Kakizaki F, Konishi N, Yara S, Miyazaki T, Hirayama T, Ikegami T, Honda A	Evaluation of gut dysbiosis using serum and fecal bile acid profiles	World J Clin Cases	10(34)	12484- 93	2022	
140)	Miyazaki T, Sasaki S, Toyoda A, Shirai M, Ikegami T, Honda A	Impaired bile acid synthesis in a taurine-deficient cat model	Adv Exp Med Biol	1370	195-203	2022	
141)	Kawata K, Atsukawa M, Ohta K, Chida T, Noritake H, Arai T, Iwakiri K, Yasuda S, Toyoda H, Okubo T, Hiraoka A, Watanabe T, Uojima H, Nozaki A, Tani J, Morishita A, Kageyama F, Sasada Y, Nagasawa M, Matsushita M, Oyaizu T, Mikami S, Ikegami T, Abe H, Matsuura K, Tanaka Y and Tsubota A	Mac-2-binding protein glycan isomer predicts all malignancies after sustained virological response in chronic hepatitis	Hepatol Commun	6	1855-69	2022	
142)	Matsumoto K, Ohfuji S, Abe M, Komori A, Takahashi A, Fujii H, Kawata K, Noritake H, Tadokoro T, Honda A, Asami M, Namisaki T, Ueno M, Sato K, Kakisaka K, Arakawa M, Ito T, Tanaka K, Matsui T, Setsu T, Takamura M, Yasuda S, Katsumi T, Itakura J, Sano T, Tamura Y, Miura R, Arizumi T, Asaoka Y, Uno K, Nishitani A, Ueno Y, Terai S, Takikawa Y, Morimoto Y, Yoshiji H, Mochida S, Ikegami T, Masaki T, Kawada N, Ohira H and Tanaka A	Environmental factors, medical and family history, and comorbidities associated with primary biliary cholangitis in Japan: a multicenter case-control study.	J Gastroenterol	57	19-29	2022	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
143)	Maeda K, Takikawa H, Aiso M, Tsuji K, Kagawa T, Watanabe M, Sato K, Sakisaka S, Hiasa Y, Takei Y, Ohira H, Hashimoto E, Ayada M, <u>Ikegami T</u> , Arakawa N, Kusuha H, Saito Y, Sugiyama Y	Frequency of null genotypes of glutathione S-transferase M1 and T1 in Japanese patients with drug-induced liver injury	Hepatol Res	52(10)	882-7	2022	
144)	井上淳, 柿崎暁, 戸島洋貴, 戸所大輔, 小川浩司, <u>池上正</u> , 西村知久, 國方彦志, 是永匡紹	眼科医に対する肝炎ウイルス検査に関するアンケート調査	肝臓	63(2)	87-9	2022	○